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The vaginal inflammation and infection are one of the major female health issues, and unfortunately rather 
neglected. The anatomical structure and physiological conditions make vagina vulnerable to inflammation 
and infection, which if not successfully treated, can lead to deteriorating female health conditions. In 
pregnant patients, the pregnancy outcome can be severely affected. Although a standard treatment for 
vaginal infection is available, it is often not successful and recurrence rates are high. Therefore, a patient-
focused drug development targeted at the vaginal inflammation and infection is the current social 
demand. Research and practice have shown that the topical treatment by the drugs against vaginal 
inflammation and infection can be superior comparing to the classical oral drug administration. However, 
the thick vaginal mucus lining the luminal surface of vagina and cervix, which protects the underlying 
tissue, limits the ability of a drug to reach vaginal mucosa. The success of mucosal delivery is highly 
dependent on a suitable drug carrier. Current dosage forms suffer from limited residence time at 
administration site and unpleasant leakage of dosage forms residues due to the self-cleansing action of 
the vagina, resulting in a reduced therapeutic effect. Therefore, liposomal drug delivery systems, with the 
ability to incorporate poorly soluble drugs and assure their stability, would be suitable for this purpose. 
Moreover, the modification of liposomal surface with mucoadhesive or mucoresistant polymers, might 
further enable improved mucosal drug delivery by providing prolonged residence time or rapid mucus-
penetration, respectively. 
We selected chitosan as a mucoadhesive polymer due to its biocompatibility, low toxicity and intrinsic 
anti-microbial potential. By combining the liposomal carrier and the mucoadhesive chitosan, an optimized 
vaginal drug delivery system with specific, prolonged and controlled drug release properties might be 
developed. Alternatively, improved drug delivery to vaginal mucosa can be provided through 
mucoresistant properties of the delivery system. Polyethylene glycol (PEG) plays an important role in this 
approach, and PEGylated liposomes enable controlled drug release in close proximity to the vaginal 
epithelium. Three model drugs/active ingredients were tested in mucoadhesive/mucoresistant liposome-
based delivery systems, namely clotrimazole, resveratrol and interferon. Particularly interesting were the 
anti-oxidative and anti-inflammatory properties of resveratrol, which has a great potential in the 




accompanied by poor stability limit its therapeutic effects. Liposomal system enhanced its activities and 
confirmed its potential. 
The in vitro drug release and ex vivo penetration confirmed a sustained release of all liposomally-
associated drugs/active molecules. PEGylated liposomes (mucoresistant) assured improved penetration 
of interferon. By modulation of liposomal surface properties to be either mucoadhesive or mucoresistant 
it is possible to achieve prolonged residence time or deeper penetration of drug within vaginal epithelium, 
respectively. Moreover, the system can be modified for the different drugs, regardless of their molecular 
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Recently released data (the 2014 STD Surveillance Report) from the U.S. Centers for Disease Control and 
Prevention indicate a significant increase in the sexually transmitted infections (STIs) in 2014, the first rise 
in sexual transmitted diseases (STDs) incidents since 2006. Although human immunodeficiency virus (HIV) 
infections received relatively lot of attention, non-HIV genital infections are clearly a neglected area of 
biomedical research. Yet, genital infections represent a major public health problem with increasing 
incidence, affecting both female and male population. Due to the anatomical structure and physiological 
functions of the vagina, women are predisposed to pathogenic vaginal infections. Since vaginal infections 
are readily transmitted to men, a more appropriate terminology would be to use the term genital 
infections. However, this project focused on the optimization of local vaginal therapy and the term vaginal 
infections is applied throughout the thesis. 
Vaginal infections are common in women of all ages and if not treated adequately, are associated with 
serious consequences such as infertility, preterm delivery, increased neonatal mortality and morbidity as 
well as induction of malignancy (Fenton and Lowndes, 2004). In spite of the concerns and the serious 
consequences, the therapeutic options offered by conventional treatment remain to be limited. Better 
understanding of the healthy and diseased conditions, and design of advanced drug delivery systems to 
assure improved therapy outcome are the prerequisites for successful treatment of vaginal infections and 
inflammation. 
Any condition causing an inflammation of the vagina is generally referred to as vaginitis, one of the most 
frequent gynecological problems faced by women of all ages (Hainer and Gibson, 2011). Vulvovaginal 
candidiasis, trichomoniasis and bacterial vaginosis are the most common causes of vaginitis (Owen and 
Clenney, 2004). In general, the topical treatment is found to be as effective as oral drug therapy in the 
treatment of vaginitis, and is preferential due to minimal adverse effects. However, the local 
characteristics of infected vaginal tract might influence the efficacy of topically administered dosage forms 
and limit the efficacy of the treatment. These characteristics need to be considered in the design of 
effective topical vaginal therapy (Palmeira-de-Oliveira et al., 2015). Moreover, the Herpes simplex virus 
(HSV) and Human papilloma virus (HPV), the most common vaginal viral infections, represent a specific 
therapeutic challenge (Viera et al., 2010). The elimination of virus is a tough challenge for current 
treatment options resulting in a high recurrence and increasing number of infections. Thus, the search for 




and biologicals. Nanomedicine has the potential to address some of the challenges of the limited therapy 
success and improve the therapy outcome (Vanić and Škalko-Basnet, 2013). 
 
1.1 Common vaginal infections 
1.1.1 Vulvovaginal candidiasis 
Candida albicans is a natural part of the normal vaginal microflora of women in reproductive age, yet it is 
a pathogenic fungus potentially causing mucosal infection and can be referred to as an opportunistic 
pathogen. It is accountable for up to 92 % of vulvovaginal candidiasis incidents (Sobel, 1997). Disturbance 
of the normal microbial balance or a weakened host defense can result in infection caused by Candida 
(Pavelić et al., 2005). The infection is initiated by the adhesion of Candida to epithelial cells (Johal et al., 
2014). Definite factors that cause the virulence of Candida are not clear; however, pregnancy, diabetes 
and the use of antibiotics or oral contraceptives can increase the perceptibility to infection. Although it is 
not considered a sexually transmitted disease, sexual transmission do occur. Up to 75 % of women will 
experience a vaginal candidiasis infection at least once in their lifetime and several endure recurrent 
infections (Palmeira-de-Oliveira et al., 2015). The conditions can be treated both orally and locally, and 
the efficacy of the two approaches is considered equivalent. Nevertheless, local drug therapy presents 
several advantages such as reduced incidence of adverse effects and avoidance of extensive drug 
absorption (das Neves et al., 2008). Mechanisms involved in the pathogenicity of candidiasis, such as the 
ability to form biofilms is possibly also relevant in the explanation of treatment failure (Palmeira-de-
Oliveira et al., 2015). Imidazole-derivative anti-fungal agents, including clotrimazole, are main topical 
treatment regimens of candidiasis (Owen and Clenney, 2004). 
 
1.1.2 Herpes simplex virus (HSV) 
HSV is highly contagious, and oral or genital sites are easily infected via direct contact with infected 
individuals. Damaged skin or mucosal surfaces permit entry of the virus that replicates within the epithelial 
cells (Cortesi and Esposito, 2008). In general, facial infection is caused by HSV-1, while HSV-2 induces 
genital herpes (Devi Kusum and Bhosale, 2009). Due to the virulence and high frequency of unrecognized 
and undiagnosed infections, HSV is one of the most common STIs. Furthermore, recurrent episodes will 




susceptibility to HIV infection make HSV a significant public health concern (Gupta et al., 2007; Gardella, 
2011). Systemic treatment by anti-viral agents, such as acyclovir, are usually standard treatment of 
symptomatic genital HSV infection. In addition to the attached systemic adverse effects, anti-viral 
treatment merely subside symptoms and duration of lesions, and does not eradicate infection or prevent 
reoccurrence (Gupta et al., 2007; Viera et al., 2010). The number of infections are increasing, and 
strategies to prevent HSV transmission such as topical viracides and the development of new anti-HSV 
products is ongoing. One approach has been to examine natural products isolated from plants for anti-
HSV activity (Docherty et al., 2005). 
 
1.1.3 Human papilloma virus (HPV) 
HPV infections are considered the most common STIs (Forcier and Musacchio, 2010; Foldvari, 2012). 
Similar to HSV, HPV is transmitted via mucosal surfaces (Patel et al., 2012). Currently, more than 120 
subtypes of HPV have been identified, of which approximately 40 can infect the human genital tract 
(Chinchai et al., 2012; Patel et al., 2012). HPV, primarily type 16 and 18, is a major cause of cervical cancer. 
Further, HPV is associated with other cancers and is principally responsible for genital warts (Forcier and 
Musacchio, 2010). To date, there is no available anti-viral therapy (Rodríguez-Gascón et al., 2015). The 
common treatment of genital warts is removal of growth, potentially combined with topical treatment. 
This is associated with pain and systemic and local adverse effects, yet not elimination of the latent viral 
infection (Fathi and Tsoukas, 2014). Developed vaccines prevent HPV infection, but only if administered 
before the sexual debut, and a curative therapy is yet to be found. One approach with great potential is 
the further development of biologicals, of which interferon alpha (IFN-α) is used as intralesional injection 
in the treatment of HPV infection (Foldvari et al., 2011). 
 
1.2 Current and perspective therapeutic approaches to vaginal infections 
1.2.1 Candidiasis: Clotrimazole 
The anti-fungal agent clotrimazole is known to be effective in the local treatment of candidiasis and is 
commonly used due to its potent local action with no major side effects (Kast et al., 2002). Clotrimazole 
formulations such as vaginal tablets (Canesten®) and gels (Candid V Gel®) are available for the local therapy 




administration suffer from limited residence time at the site of administration, impairing the therapeutic 
outcome and resulting in a need for frequent drug administration (Bilensoy et al., 2006). 
 
 
Figure 1.1: Structure of clotrimazole. 
 
Clotrimazole (Figure 1.1) is a highly lipophilic drug (log P of 3.5), and presents challenges in the formulation 
of novel dosage forms due to its poor aqueous solubility. Hence, clotrimazole was found to be a suitable 
choice of model drug for the development of optimal vaginal drug delivery system. Its incorporation in 
mucoadhesive liposomes is expected to improve the efficacy of its therapy. 
 
1.2.2 HSV infections: Resveratrol 
Resveratrol might be the active substance with unexplored potential in topical treatment of vaginal 
infections. It is a substance of natural origin, with strong anti-oxidant and anti-inflammatory effect. It 
occurs in cis and trans isomers, of which the trans-resveratrol (Figure 1.2), with the chemical name trans-
3,5,4’-trihydroxy stilbene, is the most biologically active (Mukherjee et al., 2010). Resveratrol is highly 
photosensitive and when exposed to light trans-resveratrol will convert to the cis-isomer, which is stable 






Figure 1.2: Structure of resveratrol. 
 
The many beneficial effects of resveratrol have recently gained great attention among scientists, 
nutraceutical and food industries, especially its anti-oxidant effects. Pharmacological activities of 
resveratrol such as anti-aging, anti-cancer, cardio-protective, anti-inflammatory, anti-microbial, anti-
oxidant, anti-inflammatory and anti-viral effects have been reported (Baur and Sinclair, 2006). Considering 
the local vaginal therapy, its strong anti-oxidant and anti-inflammatory effects are of great interest for the 
treatment of vaginal inflammation and infections (Bhat et al., 2001; Houillé et al., 2014). Further, the local 
administration of resveratrol has shown reduced replication of HSV in both skin (Docherty et al., 2004) and 
vagina (Docherty et al., 2005). However, resveratrol is poorly water-soluble (log P of 3.1) and its 
bioavailability and stability is rather limited (Amri et al., 2012). Hence, there is a need for a suitable drug 
delivery system that not only enables controlled drug delivery, but also protects the drug from 
environmental and chemical changes. Liposomal delivery system is expected to serve both purposes. 
 
1.2.3 HPV infections: Interferon (IFN) 
In a search for therapeutic options to treat HPV infections, recent attention has been focused on 
biologicals. Among biologicals, IFNs, naturally occurring cytokines produced by leukocytes mainly in 
immunomodulating response of viral infection, are of particular interest (Bergman et al., 2011). IFNs are 
involved in the body's natural defensive responses to foreign components such as microbes, tumors and 
antigens, and presents one of the most widely investigated and clinically used biopharmaceuticals (Baron 
et al., 1991). Their anti-viral, anti-proliferate and immunomodulatory effects have been confirmed and 
several subtypes are clinically approved for various indications. Among these subtypes IFN α-2b, with the 
trade name Intron A, is FDA-approved for indications such as chronic hepatitis B and C, malignant 




be applicable treatment, yet this includes pain and side effects due to systemic exposure. Further, this is 
not suitable treatment for latent or subclinical infections and a non-invasive approach is desirable (Foldvari 
and Kumar, 2012). Foldvari and Moreland introduced the vaginal administration of IFN α-2b, for the 
treatment of HPV infections (Foldvari and Moreland, 1997). Topical treatment provides advantages such 
as drug delivery directly to site of infection and increased efficiency at lower doses, reduced adverse 
effects due to decreased systemic levels and a more adequate treatment that include non-visible lesions 
(Hamidi et al., 2007; King et al., 2013). Like other biologicals, the IFNs are labile drugs prone to alterations 
(Karau et al., 1996). A suitable delivery system might alter the bioavailability, increase the stability and 
provide controlled release of IFN α-2b (Yang et al., 2006; Li et al., 2011).  
 
1.3 The vagina 
The human vagina is a tubular, fibromuscular organ that connects the cervix and the vulva and plays a 
major role in reproduction. It is slightly S-shaped with dimensions of 8.4 - 11.3 cm in length and 2.1 - 5.0 
cm in diameter (de Araújo Pereira and Bruschi, 2012). Histologically, the vaginal wall consists of three 
layers; the epithelial layer (stratified squamous epithelium resting on lamina propria), the muscular layer 
and the tunica adventia (Figure 1.3). 
 
 





The stratified squamous epithelium contains numerous folds, or rugae, providing distensibility and an 
increased surface area for absorption. The thickness of the vaginal epithelium is age dependent. With 
hormonal activity the thickness increases, hence, the epithelium is relatively thin before puberty (except 
in newborns), increasing in thickness after puberty and then retrieving a state similar to pre-puberty after 
menopause. Additionally, the hormone levels during the menstrual cycle also affect the epithelial 
thickness (Hussain and Ahsan, 2005). 
Although considered a mucosal tissue, vagina does not have secretory glands. However, a certain amount 
of fluid is secreted, mainly constituted of transudate from vaginal and cervical cells. Studies suggest that 
the daily production of fluid is approximately 6 g (Marques et al., 2011). The vaginal fluid is a mixture of 
several components including enzymes, enzymatic inhibitors, proteins, carbohydrates, amino acids and 
cervical mucus composing a moist surface film covering the vaginal wall. The cervicovaginal mucus forms 
a continuously renewed, semipermeable viscoelastic barrier that protects the underlying tissue from 
infection. Vaginal mucus consists mainly of water (90 - 95 %) and mucins (1 - 2 %) and has a pH around 4.5 
in healthy women of reproductive age (das Neves et al., 2015). The mucus barrier consists of two layers, 
namely; the luminal mucus layer (soluble secretory mucin) which is rapidly cleared and the unstirred 
mucus layer (membrane bound mucins) which is adherent to vaginal epithelium and undergo a slower 
physiological turnover (Wong et al., 2014; Edsman and Hägerström, 2005). Foreign particles are sterically 
trapped and effectively removed by mucus clearance, preventing pathogens from reaching the mucosal 
tissue. Nevertheless, virus has the ability to overcome this barrier and cause mucosal infection. 
Environmental changes such as changes in pH due to vaginal infections or changes in viscosity of vaginal 
fluid affect the properties of mucus. When exposed to infection, a reduction in the viscosity of vaginal fluid 
causes reduced barrier properties and an increased risk of secondary infections (Palmeira-de-Oliveira et 
al., 2015). The mucus viscosity varies also during the different phases of the menstrual cycle. A more 
watery mucus that facilitates penetration occur during the first half of the cycle, due to an increase of 
estrogen level, while progesterone originate a more viscous mucus during the second half of the cycle 
(Caramella et al., 2015). 
Vaginal pH also attributes to the protection against infections (de Araújo Pereira and Bruschi, 2012). 
Normal vaginal microflora is dominated by lactobacilli, creating a natural acidic environment by converting 
glycogen into lactic acid resulting in a pH of 3.8 - 4.2 in healthy, pre-menopausal women (Alexander et al., 
2004). The dynamic system of the vaginal flora can be affected by the presence of semen, menstrual blood 




vaginal pH is necessary for the prevention of microbial growth and vaginal infections (Mallipeddi and 
Rohan, 2010a). Exposure to unnatural products such as soap and sanitary towels or tampons might also 
threaten the healthy vaginal environment. Close contact with these foreign materials can lead to elevated 
pH, dryness and irritated mucosal tissue, thus facilitate the establishment of infection. Additionally, the 
local application of vaginal dosage forms could disturb the vaginal flora (Fichorova et al., 2011). 
 
1.4 Vaginal drug delivery 
The vagina provides a suitable site for local as well as systemic drug delivery due to its large surface area, 
rich blood supply, avoidance of first-pass metabolism, relatively high drug permeability and the possibility 
of self-insertion and removal of dosage form. Local application further provides a more concentrated 
delivery at the site of action enabling lower dose regimens. However, the vagina is often not prioritized as 
route of administration, due to factors such as gender specificity and individual or cultural sensitivities. 
Traditionally, vagina as a site for drug delivery has been considered for locally acting drugs, such as anti-
microbial, anti-viral and contraceptives. Advances in the development of vaginal drug delivery include both 
local and systemic therapy with a wide range of compounds (Baloglu et al., 2009; Srikrishna and Cardozo, 
2013). Despite the interest for this non-invasive route of administration in both the scientific community 
and pharmaceutical industry, only a few conventional vaginal dosage forms are currently available. 
Further, current dosage forms such as creams, foams, gels and tablets suffer from leakage and limited 
residence time at administration site due to the self-cleansing action of the vagina resulting in reduced 
therapeutic effect (Baloglu et al., 2009). 
The basic physiology of the vagina must be considered in the development and optimization of vaginal 
delivery systems. In order to obtain a suitable dosage form and delivery system for successful vaginal 
therapy it has to be modified for this specific route of administration. Affecting factors such as anatomy, 
presence of mucus and the changes in vaginal fluid, pH and the thickness of epithelium influence the 
efficacy of administered drug (das Neves et al., 2011b; Machado et al., 2015). Increased vaginal pH due to 
menopause, the presence of semen, menstrual blood or disease may influence the solubility and stability 
of the drug. The composition, volume and viscosity of vaginal fluids are influenced by age, the menstrual 
cycle and sexual arousal, and affecting the release pattern of the vaginal delivery systems. The vaginal 
mucus has several important physiological functions and the distribution, penetration and residence time 




the mucus barrier and reach the vaginal mucosa is highly dependent on a suitable drug carrier (Gupta et 
al., 2011; Vanić and Škalko-Basnet, 2013; Ensign et al., 2014). In parallel to the local physiological 
conditions in the vaginal cavity, the physiochemical properties of a drug such as its molecular weight, 
lipophilicity and the degree of ionization affect the possible absorption across the vaginal epithelium 
(Cicinelli, 2008). Considering local therapy, the absorption of drug is not desirable, especially in pregnant 
patients. The intended effect of the therapy (local or systemic) contributes to the choice of drug 
formulation (Srikrishna and Cardozo, 2013). 
Ideally, a vaginal delivery system should be easy to use, discreet, offer a reversible application, painless to 
the patient, cost-effective, non-toxic, non-irritating to the mucus membrane, widely available and safe for 
continuous administration (Srikrishna and Cardozo, 2013; Hussain and Ahsan, 2005; das Neves and Bahia, 
2006). All earlier mentioned challenges related to the local therapeutic effect need to be overcome to 
obtain an optimal local treatment of vaginal infections. A uniform distribution of drug throughout the 
vaginal cavity and maintenance of a sufficient drug concentration at vaginal site is necessary for a 
successful therapy. Drugs administered vaginally that have targets within the mucosa, must move through 
and penetrate the unstirred layer before it is shed or degraded. This can be achieved by adequate retention 
time at vaginal site or rapid diffusion through mucus. 
Over the last two decades, mucoadhesive delivery systems, particularly nanopharmaceuticals have been 
extensively investigated as means of improving drug delivery in different mucosal tissues, including the 
vagina (Vanić and Škalko-Basnet, 2013; 2014). Recently, Lai and colleagues proposed a mucoresistant 
approach, which considers successful drug delivery obtained by mucus-penetrating particles (Lai et al., 
2007). This approach was inspired by the evolved properties of viruses, enabling them to penetrate mucus. 
In this project, we focused on the development of liposomal delivery systems for local treatment of vaginal 
infections. To overcome the obstacles of vaginal drug delivery, such as the mucus barrier, we aimed to 
improve liposomal properties by surface modifications. Conventional (non-coated) liposomes were 






Figure 1.4: Schematic drawing representing liposomes with various surface properties; A) Non-coated, 




Mucoadhesion is a state in which a material adheres to a mucosal tissue and is held together for extended 
periods of time by interfacial forces (Smart, 2005). In respect to drug delivery, this interaction is between 
the surface of mucus and the surface of the drug delivery system. Mucoadhesion occurs in two steps 






Figure 1.5: The two steps of mucoadhesion. 
 
The event of mucoadhesion is complex and not yet fully understood. Six theories have been proposed to 
explain the mechanism (Smart, 2005), namely the electronic theory, the wetting theory, the adsorption 
theory, the diffusion theory, the fracture theory and the mechanical theory (Figure 1.6). The electronic 
theory explains adhesion as electron transfer between mucus and the mucoadhesive system forming an 
electrical double layer at the interface that generates attractive forces. The wetting theory relates to the 
ability of a mucoadhesive polymer to spread over a mucosal tissue and proposes adhesion that occurs in 
the presence of liquid, where the liquids may act as an adhesive at the interface depending on the contact 
angle between liquid and surfaces. The adsorption theory is generally the most accepted principle of 
adhesion (Vanić and Škalko-Basnet, 2014). It is based on adhesion due to the presence of intermolecular 
forces, hydrogen bonding and/or Van der Waal’s forces between the surface of mucus and the 
mucoadhesive system. The diffusion theory discusses the interpenetration of glycoprotein mucin chain to 
sufficient depth to form a semi-permanent adhesive bond between the surfaces. The mechanical theory 
proposes that liquid adhesives diffuses into irregularities present on the surfaces developing an 
interlocked structure. The fracture theory describes the force required for detachment of the two involved 
surfaces after adhesion is established. Each of the proposed theories fails to independently explain 
mucoadhesion and the actual mucoadhesion process is probably achieved through a combination of 
several mechanisms (Edsman and Hägerström, 2005; Serra et al., 2009). 
Physiological variables such as the changes in the amount of vaginal fluid may affect the 




mucoadhesive molecules, nevertheless, the degree of consolidation and strength of bonding will be 
decreased (das Neves et al., 2011b). 
 
 
Figure 1.6: The proposed theories explaining the mucoadhesion phenomenon and the factors affecting 
mucoadhesion. 
 
The use of mucoadhesiveness in vaginal drug delivery enables prolonged residence time, reduced 
administration frequency, desired distribution, controlled delivery and improved bioavailability (Vanić and 
Škalko-Basnet, 2014). The most common approach to obtain mucoadhesion in drug delivery is the use of 
mucoadhesive polymers (Smart, 2005). 
 
1.5.1 Mucoadhesive polymers 
It is generally accepted that the use of mucoadhesive polymers, either as a vehicle for delivery systems or 
as a surface-modifying material for a drug carrier, can prolong the residence time at vaginal site. A wide 
range of polymers, both synthetic and natural, has been studied for the potential use in mucoadhesive 
drug delivery. Chitosan, sodium alginate, pectin, cellulose derivatives, polyacrylates and carbomers are 
mucoadhesive polymers widely investigated in application to vaginal drug delivery (Gupta et al., 2011; 
Wong et al., 2014; Smart, 2005). An ideal polymer for a mucoadhesive drug delivery system should be non-
toxic, non-irritant, and able to form adhesive bonds with mucus and provide controlled release of 
incorporated drug. The substantial properties of the polymers affect their ability to provide 




the chains should be small enough to allow easy penetration, however, still large enough for 
entanglements to occur. Chain flexibility also affects interpenetration and entanglement. Cross-linked 
polymers show less mobility, hence, less mucoadhesion due to reduced entanglement with mucus. A 
suitable polymer concentration is necessary to obtain adequate mucoadhesion, as high concentrations 
will reduce the flexibility and too low concentration will not present adequate chains available for 
interaction with mucus. The swelling of the polymer also depends on the concentration, in addition to the 
presence of water as over-hydration reduces the strength of bonding. Mucoadhesion will be affected by 
the charge of both mucus and the polymer; consequently, pH is an important factor. Further, greater 
surface area is more accessible for interaction with mucus, thus, the particle size will affect the 
mucoadhesiveness of the delivery system (Smart, 2005; Edsman and Hägerström, 2005). 
 
1.5.1.1 Chitosan 
Chitosan is the most widely used polymer in development of mucoadhesive nanoparticles (Mallipeddi and 
Rohan, 2010a). It is a natural cationic polysaccharide consisting of glucosamine and N-acetyl glucosamine 
units (Figure 1.7). Due to its biocompatibility, low toxicity and mucoadhesive properties, chitosan is 
attractive for many pharmaceutical applications, including those for vaginal use (Valenta, 2005). 
 
 
Figure 1.7: Structure of chitosan. 
 
The mucoadhesive properties of chitosan can be explained by the electronic theory. Electronic interactions 
between the positively charged chitosan and the negatively charged mucin are considered the reason for 
its strong adhesion to mucosal surface (Vanić and Škalko-Basnet, 2014). Chitosan is additionally suited for 
repeated adhesion, as it does not become inactivated after the first contact with mucus and no reduction 




of expressing stronger mucoadhesiveness in acidic pH, which is favorable for drug delivery at vaginal site 
(Krajewska et al., 2011). Its mucoadhesiveness ensures localized drug release and the use of chitosan in 
drug delivery systems enables a controlled and sustained release of incorporated drug (Andersen et al., 
2015). Additionally, chitosan enhances mucosal penetration by opening the tight junctions between 
mucosal epithelial cells allowing drug delivery to the deeper epithelial layers which is often desirable 
(Mallipeddi and Rohan, 2010a). 
Another property of great interest considering the local treatment of vaginal infections is the intrinsic anti-
bacterial and anti-fungal activity of chitosan. The anti-microbial activity against common pathogens 
associated with vaginal infections is confirmed. The mechanism of action include chitosan interaction with 
the fungal cell walls (Palmeira-de-Oliveira et al., 2015; Krajewska et al., 2011). Additionally, low molecular 
weight chitosan show anti-biofilm activity against Candida, interfering with the microbial virulence and 
potential recurrence (Silva-Dias et al., 2014). Its anti-biofilm activity is confirmed in both healthy and 
disease-influenced pH condition, which highlights chitosan as a suitable polymer for topical vaginal therapy 
(Kandimalla et al., 2013). 
 
1.6 Nanosystems as vaginal drug delivery systems 
Nanotechnology applied to drug delivery shows a great potential, and currently, numerous of nanocarriers 
are considered as suitable drug delivery systems. Among them, polymeric micelles, dendrimers, liposomes 
and solid nanoparticles are of great interest as novel approaches to successful drug delivery (Vauthier et 
al., 2013). As drug delivery systems, nanocarriers may enable improved solubility and delivery of poorly 
soluble drugs, more specific drug targeting, enhanced permeability through biological membranes and 
greater safety and biocompatibility (De Jong and Borm, 2008; Farokhzad and Langer, 2009). These qualities 
are due to nanosystems’ unique physiochemical properties, such as their small size and consequent large 






Figure 1.8: Schematic drawing of how surface modification can improve contact between drug and 
mucosal epithelium. 
 
The cervicovaginal mucus is a major barrier for vaginal drug delivery, in terms of reaching the epithelium 
and avoidance of clearance. To achieve an effective drug delivery at mucosal site several requirements 
must be fulfilled; distribution and retention of the system on the mucosal surface, penetration into or 
through the mucus mesh and an adequate release profile of the drug (Vanić and Škalko-Basnet, 2013). 
Surface-modified nanoparticles may overcome this mucus barrier due to small size and improved surface 
properties (Mallipeddi and Rohan, 2010b) (Figure 1.8). Surface properties and the ability to involve in 
mucoadhesion or mucus-penetration, place nanoparticles as drug delivery systems in three categories, 
namely; conventional (non-mucoadhesive), mucoadhesive and mucus-penetrating (PEGylated) delivery 
systems. Two main approaches are used in the development of mucoadhesive nanosystems, namely 
designing mucoadhesive polymer-based nanocarriers and surface modification of preformed nanocarriers 
that are non-mucoadhesive originally, often applied concept (das Neves et al., 2011b). 
The liposomes were the first nanosystems described as a drug carrier in vaginal therapy (Foldvari and 







Liposomes are spherical vesicles that form spontaneously when phospholipids interacts with water 
(Akbarzadeh et al., 2013). The lipids form one or more bilayers around an aqueous core enabling the 
incorporation of drugs within or at the bilayer interface and in the inner core (Figure 1.9). 
 
 
Figure 1.9: Schematic drawing of a unilamellar liposome. 
 
Liposomes are characterized by their lipid composition, size distribution and lamellarity (Vanić and Škalko-
Basnet, 2013). Depending on vesicle size and method of preparation, liposomes appear as small 
unilamellar vesicles (SUV) with size up to 100 nm, large unilamellar vesicles (LUV) in the size range of 100 
- 800 nm or multilamellar vesicles (MLV) with a size of 500 - 5000 nm (Torchilin, 2012). The original method 
of Bangham and colleagues (Bangham et al. 1965), also referred to as the film method, is one of the most 
common methods of liposome preparation in addition to reverse phase evaporation, ultrasonication, 
detergent removal from mixed micelles by dialysis or gel filtration, freeze-thawing and extrusion (Torchilin, 




Liposomes are considered as biocompatible, biodegradable and non-toxic drug carrier. Additionally, their 
aptitude to trap both lipophilic and hydrophilic drugs, shield the functionality of unstable drugs and assure 
controlled release and site-specific delivery of the entrapped compound, make liposomes promising as 
pharmaceutical carriers (Akbarzadeh et al., 2013; Mufamadi et al., 2011). Various applications for 
liposomes are investigated, in particular as drug delivery systems, and a number of liposomal formulations 
are on the market and many more are in pipelines (Allen and Cullis, 2013). For example, AmBisone, 
DaunoXome and Doxil are liposomal formulations already approved for intravenous application (Torchilin, 
2012). Adjustments of vesicle size, charge and composition can be performed to obtain desired properties 
for intended application. The stability of liposome membrane can be increased by the incorporation of 
cholesterol, which additionally will slow down liposomal disintegration and release of incorporated drug. 
Further, surface modification, such as coating or coupling, can increase their performance and suitability 
to the specific route of drug administration (Torchilin, 2012). 
 
Foldvari and Moreland, who clinically evaluated the applicability of liposomes containing IFN α-2b in the 
topical therapy of genital HPV infections (Foldvari and Moreland, 1997), introduced liposomes as vaginal 
drug delivery system. Liposomes ability to increase solubility of poorly water-soluble drugs and protect 
drug from degradation in the presence of vaginal fluids make them suitable for vaginal application. 
Moreover, liposomes offer a sustained and controlled release of the entrapped drug at vaginal site (Vanić 
and Škalko-Basnet, 2014). However, the liquid nature of liposomal preparations is a challenge due to 
limited retention time at administration site. Assuring suitable viscosity of liposomal formulation by their 
incorporation in hydrogels, such as Carbopol (Pavelić et al., 2005) or coating the liposomal surface with 
polymers, such as chitosan (Andersen et al., 2015), enables desired formulation properties to overcome 
this challenge. When chitosan is used as a coating material for neutral PC liposomes, it is expected that 
hydrogen bonds be created between the phospholipid head groups and the cationic polysaccharide. Not 
only will this provide increased mucoadhesive properties; it will provide protection to liposomes and 
increase their stability (Filipović-Grčić et al., 2001). With a combination of liposomal carrier properties and 
the mucoadhesive properties of chitosan, development of an optimal vaginal drug delivery system with 
specific, prolonged and controlled drug release properties might be possible. 
 
Mucoadhesion have drawn a great deal of attention in drug delivery at mucosal site, with emphasis on 
surface modification of liposomes; it was agreed that mucoadhesive polymers prolong the residence time 




shown great potential, assuring sustained drug release and prolonged residence time at vaginal site 
(Andersen et al., 2015; Berginc et al., 2014). Recent findings, however, indicated that new drug delivery 
systems that are able to penetrate mucus assure closer contact with the epithelium, and improved drug 
delivery to vaginal mucosa. This hypothesis needs to be further evaluated. 
 
1.7 Mucus-penetration 
The mucus barrier protecting the mucosal surface consists of two layers as described earlier. The luminal 
mucus layer with soluble secretory mucin has a high turnover and is rapidly cleared, while the unstirred 
mucus layer with membrane-bound mucin undergoes a lower physiological turnover and slower clearance 
(Wong et al., 2014; Edsman and Hägerström, 2005). Mucus efficiently entraps most foreign particles, both 
the pathogens causing infection and nanocarriers intended for mucosal drug delivery, preventing them 
from reaching the epithelial surface. Nevertheless, virus have the ability to overcome this barrier and 
establish mucosal infection. In order to achieve a successful local drug delivery to mucosal tissue the 
delivery system needs the ability to penetrate into or through the mucus mesh, uniformly distribute the 
drug to the underlying tissue and maintain a sufficiently high drug concentration at the site of action (Vanić 
and Škalko-Basnet, 2014). A recently proposed alternative approach to obtain these objectives is the 
imitation of the evolved properties of viruses, enabling them to penetrate mucus and cause infection (Lai 
et al., 2007; Cone, 2009). 
Mucins, high molecular weight glycoproteins, form a tight mesh network and the mucin fibers in healthy 
vaginal mucus are found to have a diameter in the range of 50 - 1800 nm, with an average of 340 ± 70 nm 
(Lai et al., 2010). Particles larger than the pore size of the mucin fibers will be unable to enter mucus due 
to steric obstruction, however, this does not necessarily mean that smaller particles will be able to 
penetrate the mucus layer (Wong et al., 2014). The heterogeneous pore size of the mucus generates a 
sieving effect comparable to size-exclusion chromatography, hence, small particles are likely to enter 
smaller pores and retain in mucus, while larger particles unable to enter small pores will diffuse more 
rapidly (Lai et al., 2007). 
In addition to the physiological characteristics of mucus and the size of nanocarriers, the surface properties 
are also essential for mucus-penetrating systems (Wong et al., 2014). It has been shown that HPV with the 
average size of 55 nm could rapidly diffuse through mucus, while HSV, with an approximate size of 180 nm 




shown to be due to adhesive interactions and not the steric obstruction. Despite the entrapment in mucus, 
HSV has the ability to reach mucosal surface and cause infection; this might be facilitated by compromised 
physiochemical properties of mucus (Lai et al., 2010). The carrier size controls to which extent carriers will 
fit in the pores of mucus, while the surface charge determines the interaction with the negatively charged 
mucin fibers. In contrast to the target of the mucoadhesive drug delivery systems which is the prolonged 
contact time with mucus, the mucoresistant carriers surface is desirable for successful drug delivery by 
mucus-penetrating particles. In the approach based on the administration of mucoresistant systems, 
polyethylene glycol (PEG) plays an important role. 
 
1.7.1 PEG 
Polyethylene glycol (PEG) is an uncharged hydrophilic polymer (Figure 1.10) widely applied in 
pharmaceutical formulations, including those for topical vaginal therapy. It is non-toxic and known to 
increase the in vivo circulation time of proteins and liposomes (Allen and Cullis, 2013). Surface modification 
by PEG (PEGylation) can enable liposomes to avoid interception by the immune system and improve their 
steric stability (Mufamadi et al., 2011). PEGylated liposomes are often referred to as stealth liposomes. 
 
 
Figure 1.10: Structure of polyethylene glycol (PEG). 
 
Extensive amounts of literature describes PEG as a polymer with strong mucoadhesive properties 
supported by the diffusion theory (Wang et al., 2008). Recent findings, however, show that PEG possess 
mucoresistant properties. When used as a coating material, PEG generate mucus-penetrating particles by 
minimizing the adhesive interactions with vaginal mucus allowing particles to efficiently penetrate the 
cervicovaginal mucus (Tang et al., 2009; Lai et al., 2007; Cu and Saltzman, 2008). The surface density and 
the molecular weight of PEG affect the diffusion rate through mucus and the recent findings indicate that 




mucus (Ensign et al., 2012; Lai et al., 2007; Mert et al., 2012). This enables a closer contact with the 
mucosal surface, improved drug effectiveness and a successful therapeutic effect is possible. 
The development of an optimal vaginal drug delivery system might be possible by utilizing the carrier 
properties of liposomes combined with the mucoresistant properties provided by PEG, enabling a 
controlled drug release in close proximity to the vaginal epithelium. 
 
To optimize the vaginal drug therapy of common vaginal infections, we have focused on two approaches; 
the modification of liposomal surface and use of natural-origin anti-virals. The mucoadhesive polymer 
chitosan was used at coating material to obtain mucoadhesive liposomes, while PEGylation was applied to 
develop mucus-penetrating liposomes. 
 
 
 Aims of the study 
21 
 
2 Aims of the study 
 
The overall aim of this project was the development and optimization of a drug delivery system for 
improved topical therapy of vaginal infections. To achieve this goal, we selected three drugs/active 
ingredients with high potential for improved therapy, namely clotrimazole (contemporary registered drug 
for vulvovaginal candidiasis), resveratrol (a potential candidate for treatment of genital HSV) and 
interferon α-2b (a potential drug for genital HPV). To optimize their delivery and assure their stability in 
vaginal environment, we separately incorporated the three drugs/candidates in surface-modified 
liposomes. 
The specific aims can be presented as following: 
 To demonstrate the capacity of liposomes to entrap both lipophilic and hydrophilic substances of 
different molecular size, confirming their suitability as nanocarrier 
 To develop mucoadhesive liposomes enabling a prolonged retention time at vaginal site as well as 
providing localized effect avoiding systemic absorption, an important feature considering therapy 
of pregnant patients 
 To optimize the mucoadhesiveness of the developed system and the effect of polymer 
concentration on the mucoadhesive properties 
 To develop mucus-penetrating liposomes providing drug release in close proximity to vaginal 
epithelium 
 To demonstrate the sustained release of liposomally-associated drug 
 To confirm the stability of the formulations in the vaginal environment 
 To confirm the safety and non-irritability of the delivery system in vivo 
 In the case of resveratrol; to confirm that liposomal system enhances the anti-oxidative and anti-
inflammatory activities of resveratrol 
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3 Summary of papers 
3.1 Paper I 
In this paper, we developed mucoadhesive liposomes aiming to assure localized effect and efficient drug 
delivery at vaginal site. 
Clotrimazole-containing liposomes were prepared by probe sonication to be of desired vesicle sizes and 
liposomal surface was modified by polymer coating to assure mucoadhesive properties. Low molecular 
weight chitosan was used as coating polymer in concentrations of 0.1, 0.3 and 0.6 % (w/v), respectively. 
Non-coated and chitosan-coated liposomes were characterized in regards to vesicle size, surface charge, 
entrapment efficiency and phosphatidylcholine content. Franz cell diffusion system was used to determine 
in vitro clotrimazole release and ex vivo penetration, using cellophane membrane and sheep vaginal tissue 
(from pregnant animals), respectively. Further, the in vitro mucoadhesiveness was measured by 
determination of mucin-binding potential in pH similar to the condition in healthy vaginal environment 
(pH 4.6). 
Probe sonication reduced the liposomal size resulting in two distinguished distribution peaks, indicating a 
bimodal size distribution with a rather high polydispersity index (PI). With the increase in sonication time, 
the PI values decreased resulting in liposomes of the desired size range (111 ± 16 nm). When liposomes 
were coated with chitosan, an increase in size was seen in addition to an increase in zeta potential. The 
change in vesicle size and surface charge was corresponding to the increase in polymer concentration, 
indicating that coating actually took place. The in vitro release studies confirmed a prolonged release of 
liposomally-associated clotrimazole compared to clotrimazole solution (propylene glycol). Interestingly, 
the release of drug was slower from non-coated liposomes compared to chitosan-coated liposomes. The 
ex vivo penetration experiments, however, displayed a similar penetration of clotrimazole from non-
coated and chitosan-coated liposomes. Nevertheless, liposomally-associated clotrimazole penetrated 
significantly less compared to clotrimazole solution, preventing undesired penetration through vaginal 
tissue. Chitosan coating on liposomal surface was shown to be available for close interaction with mucin, 
confirming the mucoadhesive potentials provided by chitosan. A superior mucin-binding potential was 
seen for liposomes coated with low polymer concentration (0.1 %). 
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Liposomal delivery systems provided sustained delivery of entrapped clotrimazole and the mucoadhesive 
properties of chitosan-coated liposomes indicate a prolonged residence time within the vaginal cavity, 
assuring high levels of drugs at mucosal site, yet a limited drug absorption, suitable for the therapy of 
pregnant patients. 
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3.2 Paper II 
In the second paper, we aimed to demonstrate that the mucoadhesive liposomes are a suitable delivery 
system for resveratrol, enabling controlled drug delivery at vaginal site and protection of entrapped 
resveratrol from environmental and chemical changes, resulting in improved resveratrol activities. 
Resveratrol loaded liposomes were brought to desired vesicle size by extrusion through polycarbonate 
membranes with defined pore size. Coating of liposomes was performed in the presence of unentrapped 
resveratrol with low molecular weight chitosan in concentrations of 0.1, 0.3 and 0.6 % (w/v), respectively. 
Vesicles were characterized for size, size distribution, surface charge, entrapment efficiency and surface-
availability of chitosan. Mucin-binding potential was measured to determine the in vitro 
mucoadhesiveness of the system in pH conditions corresponding to both healthy vaginal environment (pH 
4.6) and pH occurring during vaginal bacterial infection (pH 7.4). Franz cell diffusion system was used to 
determine in vitro resveratrol release. To confirm the in vitro anti-oxidative activities of resveratrol, the 
DPPH (1,1-Diphenyl-2-picrylhydrazyl) and ABTS•+ (2,2’-azino-bis(3-ethyl benzothiazoline)-6-sulfonic acid 
diammonium salt) radicals scavenging activities were measured and compared to the well-known anti-
oxidants vitamin C and vitamin E. Superoxide dismutase (SOD) activities in lipopolysaccharide (LPS)-
induced J774.1 cells were measured to compare the anti-oxidative activity of resveratrol in solution and 
liposomal resveratrol. To compare the in vitro anti-inflammatory activities, the effects on the nitric oxide 
(NO) production, tumor necrosis factor (TNF)-α and interleukin (IL)-β in LPS-induced macrophages were 
measured. 
The chitosan-coated liposomes with a mean vesicle size 212 nm exhibited high resveratrol incorporation 
(77 %). The system exhibited necessary mucoadhesiveness regardless of pH, with superiority of coating 
with low chitosan concentrations (0.1 %), corresponding to the measured surface-available chitosan for 
the respective test samples. In vitro release study showed the ability of liposomes to provide sustained 
release of resveratrol over a period of 8 hours. Resveratrol expressed a stronger radical scavenging activity 
for ABTS+• radicals compared to DPPH free radicals, with superior ABTS+• scavenging activity in lower 
concentrations compared to vitamin C and vitamin E. Liposomal resveratrol showed a superior SOD activity 
(26 %) compared to resveratrol solution (20 %). A concentration dependent NO production inhibition with 
a 50 % inhibitory concentration of 9.6 and 13.5 μg/mL was found for liposomal resveratrol and resveratrol 
solution, respectively. Liposomal resveratrol (10 μg/mL) inhibited 70 % of TNF-α production compared to 
52 % inhibition by the resveratrol solution. Liposomal resveratrol further inhibited the IL-β production by 
62 % compared to a 60 % inhibition by the resveratrol solution. 
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Resveratrol was confirmed to be a strong anti-oxidant and anti-inflammatory compound with enhanced 
activity when in liposomal formulation. Mucoadhesive liposomes assuring prolonged resveratrol release 
and retention time at vaginal site might serve as improved delivery system for resveratrol-based localized 
treatment of vaginal inflammation and infection mainly caused by HSV. 
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3.3 Paper III 
In the work presented in paper III we developed mucus-penetrating PEGylated liposomes containing 
interferon (IFN) α-2b aiming to improve localized drug delivery to vaginal mucosa targeting the HPV-
induced inflammation and infections. 
Liposomes coated with low molecular weight polyethylene glycol (PEG) and containing IFN α-2b of desired 
vesicle size were prepared by the extrusion through polycarbonate membranes. The PEGylated liposomes 
were characterized regarding vesicle size, size distributions, surface charge and entrapment efficiency. The 
in vitro IFN α-2b release and ex vivo penetration experiments were performed in Franz cell diffusion system 
in the presence of vaginal fluid simulant (VFS), using polyamide membrane and sheep vaginal tissue (from 
pregnant animal), respectively. PEGylated nanoparticles are expected to avoid interactions with mucin, 
hence, the in vitro mucin-binding potential was measured to confirm the mucoresistant properties of the 
PEGylated liposomes. The stability of the system in the presence of biological fluids was explored by 
determining possible drug leakage from liposomes when mixed with semen fluid simulant (SFS) and VFS. 
PEGylated liposomes containing IFN α-2b exhibited a monodisperse size distribution with a mean vesicle 
size of 181 nm and an entrapment efficiency of 81 %. A retained release was seen for both IFN α-2b 
solution and liposomally-associated IFN α-2b, even after 8 hours. However, the penetration through the 
sheep vaginal tissue was prominent, and a distinct increased IFN α-2b release from PEGylated liposomes 
was seen compared to IFN α-2b solution (Intron A buffer). A significantly (p < 0.001) reduced mucin-binding 
efficiency within the different pH conditions was expressed by the PEGylated liposomes compared to both 
conventional non-coated liposomes and chitosan-coated liposomes (0.1 %, w/v). The stability of PEGylated 
liposomes in a simulated vaginal environment and in the presence of SFS was confirmed, with a minor 
leakage of merely 5.1 % of the liposomally entrapped IFN α-2b. 
The absence of interactions between mucin and PEGylated liposomes and the ability of the liposomally-
associated IFN α-2b to penetrate through vaginal tissue indicate that the system enables drug delivery in 
close proximity to vaginal epithelium. The stability of PEGylated liposomes in a simulated vaginal 
environment and in the presence of semen fluid simulant strengthens the potential of the system as local 
treatment of HPV infections. 
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4 Experimental section 
 
Materials and methods applied in this work are thoroughly described in papers I-III and the following 
presentation of methods comprehend merely an overview of the procedures as a background for the 
discussion in Chapter 5. In addition, the methodology not included in the papers is explained in more 
details. 
 
4.1 Preparation and characterization of liposomal formulations 
The preparation, characterization and further evaluation of liposomal formulations were done according 
to the schematic presentation in Figure 4.1. 
 
 
Figure 4.1: Schematic representation of the approach and methods used in the study. 
CLZ: Clotrimazole, RES: Resveratrol. 
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 In brief, liposomes made of phosphatidylcholine (Lipoid S-100) were prepared by the thin film method. 
Lipophilic drug was added to the lipid phase and dissolved prior to film formation, while hydrophilic drug 
was added to the aqueous phase applied for re-suspension of the lipid film. Polyethylene glycol (PEG) was 
added to the lipid phase in the preparation of PEGylated liposomes. Chitosan coating was performed after 
vesicle size reduction, either in the absence (clotrimazole) or in the presences (resveratrol) of free drug. 
Free drug was separated from liposomally-associated drug by suitable separation methods and 
appropriate drug detection method for the various preparations was applied. Vesicle size distribution and 
zeta potential measurements were performed both prior to and subsequently to chitosan coating. 
Formulations with desirable properties were further evaluated in respect to mucoadhesive/mucoresistant 
properties and drug release profile. 
The anti-oxidative activities of resveratrol were examined and the effect of liposomal entrapment of 
resveratrol on the anti-oxidative and anti-inflammatory activities was investigated. 
 
4.2 Differential interference contrast (DIC) microscopy 
To explore a possible difference in the appearance of conventional non-coated, chitosan-coated and 
PEGylated liposomes, aliquots of the liposomal formulations were studied by differential interference 
contrast (DIC) microscopy (GE Healthcare, Buckinghamshire, UK). Non-coated, chitosan-coated (0.1 %, 
w/v), and PEGylated liposomes containing IFN α-2b were prepared as described above. Aliquots (5 µL) 
from respective samples, and highly diluted samples (1:1000 in distilled water) were applied to microscope 
slides (Gerhard Menzel GmbH, Braunschweig, Germany) and a cover slip (VWR International BHD Prolab, 
Leuven, Belgium) was placed onto sample. Cover slip was fixated to the microscope slip by nail polish to 
avoid unwanted motion. 
All images were made at the following settings; channel: fluorescein isothiocyanate (FITC), exposure: 10 
milliseconds and excitation: differential interference contrast (DIC). 
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4.3 Safety and non-irritability in vivo 
The aim of the in vivo study was to detect any visual indication of local irritation of vaginal mucosal tissue 
due to application of the developed mucoadhesive drug delivery system. All formulations were prepared 
and modified (size reduction and chitosan coating) according to the methods described in paper I. 
The local vaginal application of liposomal preparation was done in sheep undergoing experiments to study 
maternal and fetal hemodynamics in pregnant sheep (n=10). The animals were randomly divided into five 
groups, each receiving different formulation, namely; I) Non-coated liposomes containing clotrimazole, II) 
0.1 % chitosan-coated liposomes containing clotrimazole, III) 0.6 % chitosan-coated liposomes containing 
clotrimazole, IV) empty non-coated liposomes and V) clotrimazole solution (propylene glycol). Samples of 
10 mL were applied when animal was under general anesthesia. Photographical documentation of the 
mucosal vaginal tissue was made prior to application and approximately 3 hours after application. The 
application of respective samples (10 mL) was repeated after 6 days and additional before- and after- 
images were made. 
The study was performed at the Laboratory Animal Center at the University of Oulu, and approved by the 
National Animal Experiment Board in Finland. 
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5 Results and discussion 
 
The aim of this work was the development and optimization of liposomal drug delivery system for 
improved topical treatment of vaginal infections. Liposomes have the ability to incorporate a wide range 
of compounds, and provide protection to sensitive molecules such as resveratrol and IFN α-2b. 
Successful delivery of drugs intended for mucosal vaginal tissue depends on the ability to overcome the 
obstacles related to the vagina as administration site. By modifications of liposomal size and surface 
properties, an adequate retention time at vaginal site or rapid diffusion through mucus can be achieved. 
Liposomal carrier properties were combined with the mucoadhesive properties of chitosan and the 
mucoresistant properties of PEG, respectively. To confirm the mucoadhesiveness/mucoresistance of the 
nanosystems, the interactions with mucin and the ability to provide  sustained and controlled drug release 
were evaluated. 
Where applicable, the properties of liposomes as a nanocarrier in respect to protection and enhanced 
efficacy of incorporated active molecule were explored and confirmed. 
 
5.1 Characterization of liposomal size, surface charge and entrapment 
efficiency (Paper I - III) 
The effectiveness of local drug delivery administered to the vaginal tissue is determined by the 
physicochemical characteristics of the delivery system. The vesicle size affects the ability to fit within the 
mucin pores, while the particles surface charge and surface properties manipulation may act on system’s 
attraction or repulsion to mucus. Thus, the main focus in the development of a delivery system aiming for 
local therapy at the mucosal site is controlling the particle size, surface charge and surface properties 
(Vanić and Škalko-Basnet, 2013). However, to assure efficient drug therapy, a sufficient drug load within 
the nanocarrier is crucial. 
Preparation of liposomes by the thin film method yields MLVs with a heterogeneous size population often 
larger than 1 µm (Samad et al., 2007). A variety of size reduction methods, including the probe sonication, 
gel chromatography and extrusion, can be applied to achieve desired vesicle size. Smaller liposomes with 
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a more uniform size distribution are preferred due to larger surface area and improved drug delivery 
properties. However, the decrease in vesicle size can affect the drug loading capacity and must be 
considered and often compromised. 
When aiming for mucosal drug delivery at vaginal site, relatively little is known about the effect of vesicle 
size. das Neves and colleagues suggested that nanocarriers in the size range of 200-500 nm are superior 
compared to both smaller and larger nanosystems (das Neves et al., 2011b). Additionally, it was reported 
that the number of liposomes penetrating the intestinal mucous layer increased when the liposomal size 
was reduced to approximately 100 nm for both non-coated and chitosan-coated liposomes (Takeuchi et 
al., 2001). 
 
5.1.1 Clotrimazole-containing liposomes 
Probe sonication was chosen as size reduction method for the liposomes containing clotrimazole, and time 
of exposure was modified to achieve a desired vesicle size (around 200 nm). The sonication generated two 
distinct peaks indicating a bimodal size distribution with a relatively high, yet acceptable polydispersity 
index (PI below 0.7), in agreement with literature data on sonicated vesicles (Andersen et al., 2015). Due 
to bimodal size distribution, a multimodal distribution model (NICOMP distribution) was found suitable 
for the vesicle size determination. Liposomes sonicated for 4 min (2 x 2 min) showed a more prominent 
assembly of vesicles in the targeted size range (Table 5.1). 
 
Table 5.1: Characterization of liposomes containing clotrimazole (n=3) 
 
* Polydispersity index 








(%) Peak 1 (nm) Intensity (%) Peak 2 (nm) Intensity (%) 
1 317 ± 47 56.8 40 ± 5 41.0 0.58 23.2 ± 2.5 
2 234 ± 31 53.9 36 ± 5 43.8 0.46 25.0 ± 0.5 
2 x 2 111 ± 16 83.1 29 ± 4 16.9 0.46 16.5 ± 4.5 
 




With increased sonication time, the PI values decreased, as expected. Size reduction by sonication is 
known to cause a loss of incorporated drug, hence, the exposure to strain by sonication force was kept to 
a minimum. The effect of sonication on the reduction in clotrimazole entrapment efficiency was detectable 
for the liposomes sonicated longer than 2 min. Compared to literature reporting liposomal clotrimazole 
entrapment of over 30 % (Pavelić et al., 1999; 2005) and 90 % (Ning et al., 2005) the entrapment was 
lower, however, the literature reports different sonication conditions or lipid compositions used in the 
compared data. Despite the rather low entrapment efficiency, we decided that the drug load was sufficient 
to proceed with the selected liposomal size. 
 
The coating of the liposomal surface resulted in an increase in the vesicle size as expected (Karn et al., 
2011). To explore the influence of polymer concentration on liposomal properties, the coating was 
performed with 0.1, 0.3 and 0.6 % (w/v) low molecular weight chitosan, respectively. We have selected 
different concentrations of low molecular weight chitosan as it is known that low molecular weight 
chitosan exhibits stronger mucoadhesive and anti-microbial properties as compared to chitosan of higher 
molecular weight (Dash et al., 2011). 
 
Table 5.2: Characterization of non-coated and chitosan-coated liposomes containing clotrimazole (n=3) 
 
* Polydispersity index. 









Peak 1 (nm) Intensity (%) Peak 2 (nm) Intensity (%) 
- 107 ± 3 54 ± 3 27 ± 3 46 ± 3 0.34 - 1.6 ± 0.2 
0.1 135 ± 21 53 ± 6 42 ± 9 45 ± 5 0.29 25.9 ± 4.0 
0.3 141 ± 6 64 ± 6 48 ± 5 35 ± 6 0.27 35.6 ± 1.9 
0.6 190 ± 8 58 ± 6 54 ± 2 42 ± 6 0.29 43.8 ± 3.3 
 




Results shown in Table 5.2 confirm an increasing vesicle size after chitosan coating. Further, the polymer 
concentration was shown to influence the vesicle size, with higher chitosan concentration (0.6 %) resulting 
in larger vesicle size than liposomes coated with lower chitosan concentration. In addition, a reduced PI 
was seen for the coated liposomes. Chitosan coating is additionally expected to increase the liposomal 
zeta potential (Berginc et al., 2014); a change in the surface charge was detected for the chitosan-coated 
liposomes with an increase corresponding to the polymer concentrations (Table 5.2). 
The coating of clotrimazole-containing liposomes was not performed in the presence of free clotrimazole, 
hence, no change in drug entrapment was seen after the chitosan coating. 
 
5.1.2 Resveratrol-containing liposomes 
To obtain a more uniform size distribution, extrusion was chosen as a size reduction method for liposomes 
containing resveratrol. The extrusion was performed stepwise and a size of 200 nm was targeted to  assure 
an adequate drug entrapment. Desired vesicle size with a very low polydispersity was attained, indicating 
a monodisperse size distribution (Table 5.3) and Gaussian distribution gave the best fit for the 
measurements. Further, a phospholipid assay exhibited a minor loss of lipid in the extruded liposomes of 
only 5 %, confirming extrusion as a suitable size reduction method for liposomal formulations. 
 
Table 5.3: Characterization of non-coated and chitosan-coated liposomes containing resveratrol (n=3) 
 
* Polydispersity index. 




Vesicle size (nm) PI* Zeta potential (mv) Entrapment (%) 
- 206 ± 10 0.142 -3.17 ± 2.57 80 ± 4 
0.1 212 ± 11 0.172 4.15 ± 0.59 77 ± 4 
0.3 225 ± 10 0.122 14.77 ± 1.85 74 ± 6 
 




Chitosan coating resulted in increased vesicle size and zeta potential for the resveratrol-containing 
liposomes, yet the change was not as prominent as for the clotrimazole-containing liposomes (Table 5.3). 
An explanation for this might be the difference in the liposomal size and polydispersity between the two 
formulations prior to coating. The change in the size and charge was corresponding well to the respective 
polymer concentration, as expected. 
A satisfactory resveratrol entrapment efficiency over 70 % was achieved, in accordance with the literature 
(Caddeo et al., 2008; Kristl et al., 2009; Bonechi et al., 2012)  Polymer coating is known to increase the 
entrapment efficiency when performed in the presence of free drug (Karn et al., 2011). Chitosan coating 
was performed in the presence of free resveratrol, however, an increased resveratrol entrapment was not 
seen for the chitosan-coated liposomes. The applied phospholipid assay confirmed that the chitosan 
coating did not result in any considerable loss of lipids. The data indicate the suitability of the extrusion 
method as a size reduction method. 
 
5.1.3 PEGylated liposomes containing IFN α-2b 
Despite the uncertainty regarding the effect of vesicle size on the mucosal targeting at vaginal site, small 
particles are expected to facilitate entrapment in the mucus mesh while larger particles are prone to 
become retained on the mucus surface (Wong et al., 2014). However, larger particles (200-500 nm) 
densely coated with PEG were found to be transported more rapidly through the fresh undiluted human 
mucus, than the corresponding particles of smaller size (100 nm) (Lai et al., 2009). Hence, a vesicle size of 
200 nm was the targeted size for the PEGylated liposomes intended for mucus penetration. As for the 
resveratrol-containing liposomes, the extrusion was used as size reducing method for the PEGylated 
liposomes containing IFN α-2b, resulting in liposomes with a low polydispersity. A mean vesicle size of 181 
nm was obtained (Table 5.4) and measurements were found to fit the Gaussian distribution. 
Since phosphatidylcholine (PC) is a neutral lipid, liposomes made of PC are expected to exhibit a neutral 
or close to neutral zeta potential, as seen for the non-coated liposomes containing clotrimazole and 
resveratrol (Tables 5.2 and 5.3). However, the PEGylated liposomes exhibited a negative zeta potential 
(Table 5.4). This is believed to be a result of the selected buffer used in the liposome preparation, namely 
the Intron A buffer (the composition is presented in paper III). 
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Table 5.4: Characterization of PEGylated liposomes containing IFN α-2b (n=3) 
 
* Polydispersity index. 
 
The incorporation of IFN α-2b in liposomes can provide an increase in the IFN α-2b stability. Moreover, an 
alteration of the IFN α-2b pharmacokinetics is expected (Karau et al., 1996; Yang et al., 2006). A rather 
high IFN α-2b entrapment efficiency of 81 % was obtained. This was in accordance with the literature 
(Takeuchi et al., 1999; Vyas et al., 2006; Yang et al., 2006; Li et al., 2011). 
 
5.1.4 Microscopic evaluation of liposomes 
Differential interference contrast (DIC) microscopy is an illumination technique applied to gain an 
increased contrast in unstained, transparent samples (Davidson and Abramowitz, 2002). The method 
should minimize the pretreatment of the samples such as inclusion of a stain, freeze-fracture, etc. Two 
mutually coherent polarized light beams (separated approximately 200 nm at the focal plane) are sent 
through the liposomal samples and, by subsequently recombining these beams, the difference in the 
optical path length can be detected. The optical path length is the product of the refractive index and the 
geometric length traveled. Due to a similar geometric length for both beams, this effectively provides an 
image of the changes in refractive index along the focal plane (Boas et al., 2011). 
Non-coated, chitosan-coated (0.1 %, w/v) and PEGylated liposomes containing IFN α-2b were examined, 
both in the original concentration and highly diluted concentration, and images are shown in Figure 5.1. 
The images of samples with high liposomal concentration appear different from the diluted samples. 
Additionally, a qualitative difference was detectable in the chitosan-coated liposomes compared to the 
non-coated and PEGylated liposomes in the concentrated samples (1a-c). This was not visible in the diluted 
samples (2a-c). Even though the chitosan-coated liposomes seem to be more diffused, measurements of 
the intensity profile indicated no significant difference in the samples. 
 
Pegylated liposomes containing IFN α-2b 
Vesicle size (nm) PI* Zeta potential (mV) Entrapment (%) 
181 ± 8 0.129 - 13.33 ± 0.81 81 ± 10 
 




Figure 5.1: Microscopically depicted liposomes. Concentrated suspension; 1a) Plain (non-coated) 
liposomes 1b) Chitosan-coated liposomes 1c) PEGylated liposomes. Diluted suspension; 2a) Plain (non-
coated) liposomes 2b) Chitosan-coated liposomes 2c) PEGylated liposomes. 
 
The concentrated samples were imaged shortly after the preparation of microscope slides and the 
liposomes were moving in a random Brownian motion. The diluted samples were imaged 48 h after the 
preparation, and at this time, the samples were static. Hence, one can assume that the initially observed 
difference in chitosan-coated liposomes is a result of dissimilar movement in this formulation rather than 
its composition. To our knowledge, no reports on the examination of surface-modified liposomes by this 
technique have been reported up to now. The preliminary data indicate that the method could provide 
additional information on the nanosystem in a rather straight-forward manner, if the time is invested in 
optimization of the experimental set up. 
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5.2 In vitro mucoadhesiveness (Paper I - III) 
The natural polymer chitosan is considered biocompatible, biodegradable and mucoadhesive. Its 
mucoadhesive properties have been studied for various drug delivery systems and chitosan is a preferred 
polymer for topical drug delivery, including vaginal administration (Valenta, 2005). The cationic character 
of chitosan is the main property that renders its mucoadhesive properties and also makes it suitable as 
coating polymer for neutral PC liposomes. During the coating process, it is expected that hydrogen bonds 
be created between the phospholipid head groups of the liposomes and the cationic amino groups of 
chitosan (Perugini et al., 2000). Both the increase in vesicle size and zeta potential indicate the presence 
of chitosan on the liposomal surface and the evidence that the coating actually took place (Table 5.2 and 
5.3). 
 
5.2.1 Surface-available chitosan 
When used as a coating material, the amount of polymer interacting with the liposomes is expected to 
increase with starting amount of chitosan (Li et al., 2009; Perugini et al., 2000). To determine the presence 
of chitosan on the liposomal surface, a colorimetric assay with the anionic reactive dye (Cibacron Brilliant 
Red) was applied. The assay was performed in the presence of free chitosan, thus the binding efficiency of 
chitosan to liposomal surface was not directly measured. Nevertheless, we could see a distinguished 
change in chitosan concentration of the different formulations compared to the starting amount of 
chitosan (Figure 5.2). For the lower chitosan concentration (0.1 %), 84 % of theoretical amount of chitosan 
was detected. Further, only 54 % was detected in liposomal suspension coated with higher polymer 
concentration (0.3 %). The results show that coating with low chitosan concentration (0.1 %) provide more 
chitosan on liposomal surface. These findings are in accordance with literature (Andersen et al., 2015; Li 
et al., 2009) and corresponding to the zeta potential of respective samples. 
 




Figure 5.2: Surface-available chitosan (%) on chitosan-coated liposomes (n=3). 
* Non-coated liposomes served as a control. 
 
Since no chitosan was removed from the formulations prior to determination, one can discuss if the 
amount of surface-available chitosan is overexpressed. Yet, an incomplete detection of actual chitosan in 
the formulation indicates that some of the chitosan is concealed, possibly due to thick layer of polymer. 
Another explanation might be that chitosan interacts with liposomal surface and adsorbs onto lipid layer. 
Nevertheless, the liposome coating efficiency has been shown to be superior when using low chitosan 
concentration; Guo and colleagues found that chitosan coating of liposomes reached a saturation state 
when exceeded a 0.1 % chitosan concentration (Guo et al., 2003). 
 
5.2.2 Mucin-binding 
A successful vaginal drug delivery system should assure a uniform distribution of drug onto the mucosal 
tissue. The interaction between the drug delivery system and mucus can affect the performance of the 
system and maintaining high drug concentration at vaginal site is challenged by inadequate retention time. 
To confirm that chitosan coating on the liposomal surface is available for close interactions with mucin and 
render mucoadhesive properties to the delivery system, we tested the in vitro mucin-binding potential of 
both chitosan-coated and non-coated liposomes. Through ionic interactions, chitosan can acquire strong 
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adhesion between its cationic groups and the anionic structures of mucus, enabling prolonged retention 
time in the vaginal cavity. Commercial pig mucin (PM) is commonly used as a mucus substitute due to 
similarity in the structure and molecular weight of pig mucus and human mucus (Groo and Lagarce, 2014). 
Due to the variations in vaginal pH, especially when affected by vaginal bacterial infections, the experiment 
was performed both at pH conditions of a healthy vaginal environment (4.6) and at pH occurring in vaginal 
bacterial infection (7.4). The changes in the viscosity of mucus occurring during the menstrual cycle or due 
to vaginal infections were not accounted for, thus, the presented results are preliminary. 
The results clearly indicate that liposomes coated with the lowest chitosan concentration (0.1 %) exhibited 
a superior interaction with mucin compared to all other formulations (Figure 5.3), suggesting prolonged 
residence time at vaginal site. These results are in agreement with literature (Naderkhani et al., 2014). 
Additionally, the mucin-binding potential is corresponding to the surface-available chitosan observed for 
the respective formulations (Figure 5.2). This tendency of reduced amount of surface-available chitosan 
and reduced mucin-binding when coating is performed with high polymer concentrations is strengthened 
by the low PM binding expressed by liposomes coated with 0.6 % chitosan. 
 
 
Figure 5.3: Pig mucin (PM) binding (%) of non-coated and chitosan-coated liposomes (n = 3). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
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Non-coated liposomes are not expected to exhibit mucin-binding activity, yet a distinct binding potential 
was seen also for the non-coated formulation. Literature data show similar findings (Andersen et al., 2015; 
Naderkhani et al., 2014; Qiang et al., 2012). Physical interactions during the centrifugation step is a 
possible explanation for these results, as actual electrostatic interactions are unlikely to occur between 
mucin and neutral non-coated liposomes. 
An increased mucoadhesiveness was expected in the acidic environment due to the pKa of chitosan (6.3 
to 6.6) (Krajewska et al., 2011). However, an equal mucin-binding potential was seen for liposomes coated 
with low chitosan concentration at both pH conditions, indicating that mucoadhesion can be achieved 
regardless of vaginal pH conditions. This suggests that the mucoadhesive properties of the system should 
not be compromised due to elevated pH occurring as a result of vaginal infection or due to the presence 
of semen. 
It is expected that mucoadhesion will increase with decreasing vesicle size due to larger surface area and 
higher availability to mucin interaction. Chitosan-coated nanoparticles in sizes of about 200 nm and 300 
nm are shown to exhibit significantly enhanced mucoadhesive properties on porcine tissue, compared to 
larger particles (900 nm) (Meng et al., 2011). Hence, it is reasonable to expect that liposomes in the size 
range of 200 nm might exhibit even greater mucin-binding potential compared to liposomes in original 
vesicle size. 
 
The other approach to obtain a uniform distribution and a sufficiently high drug concentration at the site 
of action, is rapid penetration through the mucus mesh to avoid clearance and reach the epithelial surface. 
Low molecular weight PEG (20 kDa) used on vesicle surface is found to allow nanoparticles to avoid 
interactions with mucus and enable penetration of the cervicovaginal mucus. Thus, the mucin-binding 
potential of PEGylated liposomes was determined to confirm the mucoresistant effects of PEG. Compared 
to non-coated and chitosan-coated liposomes, the PEGylated liposomes did not exhibit prominent mucin-
binding activity (Figure 5.4), as expected. 
 




Figure 5.4: Pig mucin (PM) binding (%) of PEGylated, non-coated and chitosan-coated liposomes (n = 3). 
 
These findings indicate reduced mucin interaction when liposomal surface is modified with PEG, enabling 
penetration through mucus. This allows closer contact with vaginal epithelium and enables improved drug 
effectiveness. 
 
5.3 In vitro drug release (Paper I - III) 
A predictable and controlled release is essential in the development of an optimal drug delivery system. 
Surface modification of liposomes by chitosan coating was confirmed to render mucoadhesive properties 
to the delivery system, additionally, it may present improved controlled drug delivery and stabilization of 
the liposomes. To examine the release from both chitosan-coated and non-coated liposomes, an in vitro 
release study was performed. Franz cell diffusion system is generally considered the most appropriate in 
vitro method for evaluating drug release from topical formulations including those for vaginal use (Siewert 
et al., 2003; das Neves and Bahia, 2006), thus was applied in the release studies. The experimental setup 
was based on human conditions, with an acceptor medium corresponding to the pH of a healthy vaginal 
environment (4.6) and a temperature of 37 °C. To test the release of clotrimazole a setup of 24 hours was 
applied based on the mucoadhesive potential of the system, enabling a less frequent application compared 
to the vaginal dosage forms of clotrimazole that are commercially available. 





Figure 5.5: In vitro clotrimazole release (%) from non-coated and chitosan-coated liposomes (n=3). 
* Clotrimazole dissolved in propylene glycol as control. 
Modified from Jøraholmen et al., 2014 (Paper I) with permission from Elsevier. 
 
A prolonged release was confirmed for the liposomally-associated clotrimazole, compared to clotrimazole 
solution (propylene glycol) of corresponding concentration (Figure 5.5). A slower clotrimazole release was 
expected from the chitosan-coated liposomes due to the propensity of liposomes to become leaky when 
not coated. Interestingly, the non-coated liposomes showed a superior ability to sustaine the clotrimazole 
release compared to all chitosan-coated formulations. It appears that the clotrimazole release from 
liposomes is enhanced when chitosan is used as coating material. A possible explanation might be 
clotrimazoles affinity of the liposomal bilayers rather than the outer aqueous medium, whereas the 
release from chitosan-coated liposomes is promoted by the precence of chitosan. 
A limitation of the Franz diffusion system is the confined volume of the acceptor chamber, which is 
problematic when analyzing poorly soluble drugs such as clotrimazole. Even after 24 hours, all 
formulations, including the control, failed to release all incorporated drug. Possibly, this is due to the very 
limited solubility of clotrimazole in water. Nevertheless, a distinguished difference in the release of 
liposomally-assosiated clotrimazole and clotrimazole in solution could be detected. 





Figure 5.6: In vitro resveratrol release (%) from non-coated and chitosan-coated liposomes (n = 3). 
* Resveratrol dissolved in propylene glycol as control. 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
The same tendency was seen for the in vitro release of resveratrol, namely a prolonged release of 
liposomally-associated resveratrol compared to resveratrol solution (propylene glycol) in corresponding 
concentration (Figure 5.6). However, chitosan-coated liposomes expressed a more sustained resveratrol 
release compared to non-coated liposomes, unlike the release of clotrimazole. This agrees with the 
expectations of a prolonged drug release when liposomes are chitosan-coated. A possible explanation for 
the unequal effect of coating on the release of the different entrapped substance is that, although 
lipophilic, resveratrol displays a minor preference to the liposomal bilayer compared to clotrimazole. Due 
to the poor mucoadhesive properties exhibited by chitosan-coated liposomes with high polymer 
concentrations, the 0.6 % chitosan-coated liposomes were not included in the in vitro release 
determination of resveratrol. 
The release from PEGylated liposomes was compared to a control (corresponding concentration of IFN α-
2b in Intron A buffer), and the experiment was done in the presence of vaginal fluid simulant (VFS) to 
closer mimic the in vivo conditions. Both formulations failed to release the incorporated drug, yet a poor 
release of liposomally-associated IFN α-2b was seen after 6 and 8 hours (Figure 5.7). After 8 hours of 
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experiment, a considerable amount of IFN α-2b was retained within the artificial membrane. This retention 
was seen for both formulations (data not shown). 
 
 
Figure 5.7: In vitro IFN α-2b release (%) from PEGylated liposomes (n=3). 
* IFN α-2b in Intron A buffer as a control. 
 
A sustained IFN α-2b release from liposomal formulation is in agreement with literature (Qiu et al., 2005; 
King et al., 2013). 
 
5.4 Ex vivo penetration (Paper I and III) 
As for the in vitro drug release, the Franz cell diffusion system is found to be suitable in the determination 
of ex vivo tissue penetration (Sandri et al., 2004; Bonferoni et al., 2008; das Neves et al., 2013; Machado 
et al., 2015). When aiming at safe topical drug delivery applied to pregnant patients, a limited drug 
absorption is desirable, at the same time, an adequate level of drug at the vaginal site should be achieved. 
To acquire a closer approach to in vivo conditions, vaginal tissue from pregnant sheep was applied in the 
ex vivo penetration experiments. Sheep vaginal epithelium is stratified squamous tissue, similar to that of 
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human, only thinner (Moss et al., 2012). Further, no significant differences have been observed in using 
fresh or snap-frozen tissue samples (Sassi et al., 2004). 
 
 
Figure 5.8: Clotrimazole penetration (%) of sheep vaginal tissue ex vivo for non-coated and chitosan-coated 
liposomes (n=3). 
* Clotrimazole dissolved in propylene glycol as control. 
Modified from Jøraholmen et al., 2014 (Paper I) with permission from Elsevier. 
 
Liposomally-associated clotrimazole penetrated significantly less than clotrimazole in solution (propylene 
glycol). The results showed that noticeable amounts of free clotrimazole penetrated through the vaginal 
tissue whereas clotrimazole penetrated to lesser extent from all liposomal formulations (Figure 5.8). The 
data demonstrate that liposomes are able to retain associated clotrimazole on the surface of the vaginal 
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Figure 5.9: Clotrimazole distribution (%) after 24 hours ex vivo studies in sheep vaginal tissue (n=3). 
* Clotrimazole dissolved in propylene glycol as control. 
Modified from Jøraholmen et al., 2014 (Paper I) with permission from Elsevier. 
 
After 24 hours, the clotrimazole distribution was measured and the results emphasized the difference in 
the ex vivo behavior of clotrimazole in solution and liposomally-associated clotrimazole (Figure 5.9). 
Chitosan is known to act as a permeation enhancer by decomposition of the tight junctions (in intestinal 
epithelium), this is however associated with high molecular weight chitosan (Bernkop-Schnürch and 
Dünnhaupt, 2012). Our liposomes coated with low molecular weight chitosan were shown to be associated 
with a lower clotrimazole penetration through the vaginal tissue. The results indicate that liposomally-
associated clotrimazole will be retained on the vaginal tissue or within tissue, making it safe for 
administration during pregnancy. 
 
When aiming for a non-invasive treatment of HPV, reaching into vaginal mucosal tissue and obtain 
sustained concentrations within affected tissue, while avoiding high systemic levels, is desirable (Foldvari, 
2012). Compounds from the vaginal fluid might influence the performance of the delivery system, 
including the drug release (Owen and Katz, 1999). Thus, to obtain conditions that are closer to those 
encountered in vivo, the experiment was performed in the presence of VFS. The IFN α-2b penetration 
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through the sheep vaginal tissue was prominent compared to the in vitro drug release. Further, a distinct 
increased IFN α-2b penetration was seen from the PEGylated liposomes compared to control solution 
(corresponding concentration of IFN α-2b in Intron A buffer) (Figure 5.10). 
 
 
Figure 5.10: IFN α-2b penetration (%) through sheep vaginal tissue from PEGylated liposomes (n = 3). 
*IFN α-2b in Intron A buffer as control. 
 
This demonstrates that the PEGylated liposomal formulation enables IFN α-2b to reach into vaginal tissue 
to a higher extent compared to free IFN α-2b. The findings are in agreement with the liposomal delivery 
of IFN α-2b to skin; increased skin penetration of IFN α-2b was assured by liposomal formulation (Foldvari 
et al., 1999). 
 




Figure 5.11: IFN α-2b distribution (%) after 8 hours ex vivo penetration experiment. 
*IFN α-2b in Intron A buffer as control. 
 
After 8 hours, the amount of IFN α-2b retained on top of the vaginal tissue and within tissue was measured. 
An equal retention of liposomally-associated IFN α-2b and IFN α-2b solution within the tissue was seen 
(Figure 5.11). 
 
5.5 Liposomal stability 
Vesicle size and polydispersity are often parameters for the physical stability of liposomes, and retention 
of originally entrapped drug indicates the stability of the delivery system. Vesicles have a tendency to form 
agglomerates, which will behave in a different manner than single vesicles (das Neves et al., 2011a). No 
significant increase in the vesicle size of the chitosan-coated liposomes was seen after storage at 4 °C for 
one month (data not shown), indicating that the formation of agglomerates did not occur at this time 
point. 
To obtain a controlled drug release at vaginal site, the delivery system needs to sustain the physical and 
chemical properties when exposed to the vaginal environment. Local application might affect the stability 
and performance of the drug delivery system (Owen and Katz, 2005), and the stability of PEGylated 
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liposomes containing IFN α-2b in the presence of  vaginal fluid simulant (VFS) and semen fluid simulant 
(SFS) was evaluated. The composition, volume, pH and rheological properties of vaginal fluids are affected 
by age, the menstrual cycle or sexual arousal. Therefore, the exact amount of fluid is not defined, however, 
studies suggest that an average of 0.5 – 0.75 g of vaginal fluid is generally present in the vagina (Owen and 
Katz, 1999). The average volume of human ejaculate is found to be 3.4 mL (Owen and Katz, 2005), and the 
presence of semen is expected to affect the vaginal pH for hours (das Neves et al., 2011a). Based on these 
findings, the PEGylated liposomes were diluted 1:10 (v/v) with VFS and 1:1 (v/v) with SFS to determine the 
ability of the delivery system to retain entrapped IFN α-2b once exposed to vaginal environment. An 
incubation time of 2 hours was found appropriate. 
A minor leakage of merely 5.1 % of originally entrapped IFN α-2b was detected, indicating the stability of 
PEGylated liposomes in a simulated vaginal environment and in the presence of SFS. 
 
5.6 Safety and non-irritability in vivo 
Irritation of the vaginal tissue can lead to increased susceptibility to foreign pathogens and inflammation, 
hence, delivery systems for the topical application should be safe and non-irritant. Our system was applied 
in vivo to exclude any visual irritation of the vaginal mucosal tissue caused by the system. 
Non-coated and chitosan-coated (0.1 and 0.6 %, w/v) liposomes containing clotrimazole, empty non-
coated liposomes and clotrimazole in solution (propylene glycol) were applied in vivo and photographic 
documentation of tissue were taken before and after administration. Tissue was studied carefully 
examining the possible signs of redness or changes in the mucosal tissue after exposure to formulation. 
No signs of irritation of the mucosal tissue could be visually observed after the local administration of any 
of the formulations. The absence of irritation of the tissue was confirmed also after the second 
administration (data not shown). 
A change in the normal structure of mucus can be induced by the local administration of nanoparticles and 
high concentrations of applied nanoparticles might result in disruption of the mucus structure (das Neves 
et al., 2011a). Wang and colleagues demonstrated that surface chemistry might also play a role in whether 
the mucus barrier is vulnerable to disruption by nanoparticles (Wang et al., 2011). They examined the 
effect of synthetic particles on cervicovaginal mucus and found that high concentrations of mucoadhesive 
nanoparticles (200 nm) might increase the mucus pore size, allowing foreign particles to penetrate across 
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mucus to a higher extent. The consequence of continuous application of mucoadhesives on mucus 
structure should be further evaluated in vivo. 
 
5.7 Anti-oxidative and anti-inflammatory activities of resveratrol and 
liposomal resveratrol (Paper II) 
Among several beneficial effects, the strong anti-oxidant and anti-inflammatory effects of resveratrol 
presents great potential in the treatment of vaginal inflammations and infections. The vaginal 
administration of resveratrol has shown to reduce HSV replication (Docherty et al., 2005). Prior to 
evaluating the anti-viral potential of liposomes containing resveratrol, we have focused on comparing anti-
oxidative and anti-inflammatory activities of resveratrol and liposomally-associated resveratrol. 
 
5.7.1 Radical scavenging activity 
Radical scavenging assay was applied to confirm the in vitro anti-oxidative activities of resveratrol and 
liposomal resveratrol compared to other well-known anti-oxidants. The in vitro anti-oxidative activities of 
resveratrol were expressed as the amount of DPPH and ABTS+• radicals scavenged, as the UV absorbance 
will decrease equivalently to the decreasing number of radicals. We examined the anti-oxidant activity of 
resveratrol compared to the other well-known anti-oxidants vitamin C and vitamin E. All substances 
expressed a concentration-dependent radical scavenging activity (Figure 5.12). Resveratrol exhibited a 
stronger radical scavenging activity for ABTS+• radicals compared to DPPH free radicals. Additionally, a 
superior ABTS+• scavenging activity was exhibited by lower concentrations of resveratrol compared to 
respective concentrations of vitamin C and vitamin E. These results are supported by literature (Stojanović 
et al., 2001). 
 




Figure 5.12: Anti-oxidant activities (%) of resveratrol (RES), vitamin C and vitamin E (n=3). A) DPPH radical 
scavenging activity. B) ABTS+• scavenging activity. 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
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Polyphenols are a class of compounds which can easily transfer electron and resveratrol is classified under 
this group. ABTS+• radicals are more reactive with the resveratrol due to the electron transfer process 
involved, compared to DPPH which involves H atom transfer (Gülçin, 2010), resulting in superior ABTS+• 
scavenging capacity for resveratrol compared to vitamin C and vitamin E. This was confirmed by a separate 
experiment, measuring effective concentration causing 50 % decrease of radicals (EC50) (Figure 5.13). 
 
 
Figure 5.13: Anti-oxidative activity of resveratrol (RES), vitamin C and vitamin E expressed as EC50 in µM 
(n=3). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
Compared to vitamin C and vitamin E, resveratrol exhibited a stronger reactivity towards ABTS+• radicals 
than DPPH, with an EC50 of 17.15 and 3.05 μM against DPPH and ABTS+• radicals, respectively. While 
vitamin C showed an EC50 of 10.25 and 7.77 μM and vitamin E an EC50 of 7.38 and 6.64 μM against DPPH 
and ABTS+• radicals, respectively. 
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5.7.2 Effect of liposomal resveratrol 
The biological activity of resveratrol is limited due to its low solubility and chemical instability, hence these 
limitations needs to be overcome to assure use of resveratrol as a therapeutic agent. Liposomes have the 
ability to incorporate poorly soluble substances, and a satisfactory resveratrol entrapment was 
determined (Table 5.3). In addition to the ability of chitosan-coated liposomes to assure controlled release 
of resveratrol, we wanted to explore the effect of liposomal formulation on the anti-oxidative and anti-
inflammatory activities of resveratrol. 
 
5.7.2.1 Anti-oxidative activity 
Normal cellular metabolism produces low concentrations of reactive oxygen species (ROS). When exposed 
to pathogens, an increased metabolic activity and immune cell reaction is triggered causing an excess 
production of ROS, which causes oxidative stress. The process of inflammation and infection is accelerated 
due to the overproduction of free radicals and pro-inflammatory cytokines that causes prominent damage 
to cells. Anti-oxidants may impair the effect of free radicals by scavenging and inhibit this inflammation 
process. Further, an increased activity of superoxide dismutase (SOD) may restore the balance of ROS 
production. The anti-oxidant effect of resveratrol is expressed either directly by donating an electron to 
free radicals and/or providing hydrogen or indirectly by increasing the SOD activity (Gülçin, 2010; Zheng 
et al., 2010). We compared in vitro anti-oxidative activity of resveratrol and liposomal resveratrol by 
measuring the SOD activity in murine macrophages, J774.1 cells. Cells were cultured by general procedure 
and the media of the monolayer confluents of cells were replaced by the fresh media or media containing 
1µg/mL lipopolysaccharides (LPS) together with different concentration of the samples (resveratrol 
solution or liposomal resveratrol). The SOD activities of the resveratrol and liposomal resveratrol were 
expressed in percentage by comparing to corresponding control basal levels. 
 




Figure 5.14: The effects of resveratrol (RES) and liposomal resveratrol on enhancement of superoxide 
dismutase (SOD) activity (%) in LPS-induced macrophages (n=3). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
The SOD activities in lipopolysaccharide (LPS)-induced J774.1 cells were measured to compare the anti-
oxidant activity of resveratrol in solution (DMSO) and liposomal resveratrol. Compared to the basal SOD 
activity of the controls (0.2 % DMSO and empty liposomes, respectively), the activity was increased by 20 
% and 26 % for resveratrol solution and liposomally-associated resveratrol, respectively (Figure 5.14). 
These results show a significantly increased SOD activity for liposomal formulations as compared to 
solution. 
 
5.7.2.2 Anti-inflammatory activity 
Inflammation is one of the first responses of the immune system to infection and is caused by eicosanoids 
and cytokines, which are released by injured or infected cells. Pro-inflammatory cytokines such as 
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are involved in the process 
of pathological infection (Dinarello, 2000). Hence, the anti-inflammatory activities were expressed by the 
effect of resveratrol on the production of nitric oxide (NO), IL-1β, and TNF-α. 
 




Figure 5.15: The effects of resveratrol (RES), vitamin C, vitamin E and L-nitro-arginine methyl ester (NAME) 
on nitric oxide (NO) production (%) in LPS-induced macrophages (n=4). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
When treated with LPS, macrophages intensifies the NO production resulting in unstable NO radicals. The 
activity of resveratrol was expressed as percentage of NO production inhibition. A superior NO production 
inhibition was seen for resveratrol compared to the activity of vitamin C and vitamin E. Both resveratrol 
and L-nitro-arginine methyl ester (NAME) expressed a concentration dependent inhibition of NO 
production, however resveratrol was found to be more potent than NAME (Figure 5.15). 
 
Further, the inhibitory activity of resveratrol was compared to that of liposomal resveratrol. The amount 
of resveratrol required to show a 50 % inhibition of NO production (IC50 µg/mL) in LPS-induced J774.1 cells 
was reduced by liposomal incorporation (Figure 5.16). Resveratrol and corresponding liposomal 
formulation showed an IC50 of 13.5 and 9.6 μg/ml, respectively. The increased activity of liposomally-
associated resveratrol confirm the superior anti-inflammatory effect of resveratrol when in drug delivery 
system. 
 




Figure 5.16: The effect of resveratrol (RES) and liposomal resveratrol on NO production in LPS-induced 
macrophages expressed as IC50 in µg/mL (n=4). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
The production of cytokines TNF-α and IL-1β by LPS-induced macrophages in the presence of resveratrol 
(10 μg/ml) and corresponding liposomal formulation was measured and compared to a control group. A 
superior TNF-α production inhibition was seen for liposomally-associated resveratrol (Figure 5.17), with a 
52 % and 70 % inhibition for resveratrol and liposomal resveratrol, respectively. Further, the IL-1β 
production was reduced in the presence of resveratrol (Figure 5.17). Compared to the control group, 
resveratrol (10 μg/ml) and corresponding liposomal formulation inhibited the IL-1β production by 60 % 
and 62 %, respectively. 
 




Figure 5.17: The effects of resveratrol (RES) and liposomal resveratrol on TNF-α and IL-1β production (%) 
in LPS-induced macrophages (n=3). 
Modified from Jøraholmen et al., 2015 (Paper II) with permission from Elsevier. 
 
Liposomal resveratrol was shown to be superior in both the anti-oxidative and anti-inflammatory studies. 
The reason for the enhanced inhibitory effect might be an increased cellular uptake and/or maximized 
effect due to the liposomal entrapment of resveratrol. Additionally, the anti-microbial properties of 
chitosan may provide an advantage against vaginal pathogens. However, further in vivo and clinical studies 
are needed to obtain the direct evidences. 
The findings imply that liposomal resveratrol might be suitable treatment for vaginal inflammation. The 
mechanism of which resveratrol inhibits HSV production is not known (Docherty et al., 2005), however, 
the enhanced anti-inflammatory effect of liposomal resveratrol suggest an improved anti-HSV activity 







We have developed and optimized liposomal drug delivery systems for vaginal application, which can be 
either mucoadhesive or mucoresistant depending on the type of polymer used in the formulations. 
Chitosan coating of liposomes will result in mucoadhesive delivery system able to retain at the 
administration site for a sufficiently long period of time to assure drug presence at the site, whereas 
PEGylation of liposomes will results in ability of the system to penetrate deeper within vaginal epithelium 
and act on deep infections. The systems could be optimized to entrap different active molecules, as we 
have shown for three compounds of different molecular weights and solubilities. Clotrimazole 
(conventional therapeutic drug for vulvovaginal candidiasis), resveratrol (a potential candidate for genital 
HSV) and IFN α-2b (a potential biological drug for genital HPV) were separately studied in their liposomal 
formulations. An acceptable entrapment of both lipophilic (clotrimazole and resveratrol) and hydrophilic 
(IFN α-2b) molecules confirmed the system’s robustness. 
Chitosan-coated liposomes exhibited mucoadhesive properties in vitro, with superiority achieved by 
coating with low polymer concentration, demonstrating the ability to obtain prolonged retention time at 
vaginal site. Further, chitosan-coated liposomes were shown to enable controlled and prolonged release 
of associated drug as well as reduced penetration through the vaginal tissue. In vivo evaluations confirmed 
the system to be non-irritant to vaginal mucosal tissue. 
PEGylated liposomes were shown to avoid interactions with mucin, indicating mucoresistant properties, 
enabling mucus-penetration. Further, PEGylated liposomes exhibited enhanced penetration through the 
vaginal tissue enabling drug release in close proximity to vaginal epithelium. 
Resveratrol was confirmed to exhibit strong anti-oxidative and anti-inflammatory activities. These 
activities were further enhanced by the resveratrol incorporated liposomal formulations making liposomal 







Further in vivo and clinical studies are required to confirm the safety of the system, particularly the 
continuous application of mucoadhesive system to compromised vaginal epithelium needs to be 
evaluated. 
Chitosan is known to be non-toxic, the toxicity of PEG-modified liposomes should however be evaluated 
to confirm the safety in topical vaginal application. Additionally, a focus on how the local treatment might 
influence the natural vaginal flora should be included in the studies to enable the restoring of the healthy 
vaginal environment and avoid increased post-therapy susceptibility to infection. 
An evaluation of the anti-microbial activities of the mucoadhesive delivery system should be performed 
to explore the possible additional advantages against vaginal pathogens provided by chitosan coating. 
As a biological substance, the stability of IFN is limited and the stability when liposomally-associated should 
be evaluated. 
Further, the longtime stability of all liposomal formulations should be tested at different storing 
conditions. 
It would be further interesting to study the effect of PEG chain length when used in the surface 
modification of liposomes. Recent suggestions that PEG with molecular weight down to 7.5 kDa will enable 
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A B S T R A C T
The choice of drug therapy in pregnant patients suffering from vaginal infections is limited by the safety
profile of the drug. Assuring the efficient topical therapy to avoid systemic absorption is considered the
best therapy option. Chitosan-coated liposomes have been developed and optimized to assure localized
therapy of clotrimazole. Chitosan was selected as mucoadhesive polymer both to prolong system's
retention at the vaginal site and act on biofilms responsible for high recurrence of infections. Sonicated
liposomes were coated with chitosan in three different concentrations, namely 0.1, 0.3 and 0.6% (w/v).
Clotrimazole-containing (22 mg/mg lipid) chitosan-coated liposomes were in the size range of 100–
200 nm. The in vitro release studies confirmed prolonged release of clotrimazole from both non-coated
and chitosan-coated liposomes as compared to control. The ex vivo penetration experiments performed
on the pregnant sheep vaginal tissue showed that coated liposomes assured increased clotrimazole tissue
retention and reduced its penetration as compared to the control. Mucin studies revealed that the coating
with lower chitosan concentration increased the system's mucoadhesive potential, as compared to
coating with higher concentrations. These results provide a good platform for further in vivo animal
studies on mucoadhesive liposomes destined to localized vaginal therapy.
ã 2014 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
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Although the occurrence of vaginal infections in pregnancy is
common, the choice of drug therapy is rather limited (das Neves
et al., 2008). In particular, topical antifungal therapy is preferred
due to the systemic toxicity of antifungal drugs (Chang et al.,
2002). In pregnant patients, the two main therapy goals can be
summarized as (i) assuring the high local drug concentration
with concomitant avoidance of systemic absorption and (ii)
prevention of infection recurrence (Vanic and Škalko-Basnet,
2013). We propose that coating of liposomal surfaces with
chitosan can assure both of the goals. When vagina is the site of
drug administration, it is also important that both the drug and
corresponding delivery system are safe and non-irritating to the
delicate vaginal mucosa (Woodrow et al., 2009). The selection of
mucoadhesive polymer will be therefore based on its biode-
gradability, biocompatibility and confirmed mucoadhesivness.* Corresponding author. Tel.: +47 776 46640; fax: +47 776 46151.
E-mail address: natasa.skalko-basnet@uit.no (N. Škalko-Basnet).
1 Present address: University of Oslo, PharmaLuxLab, School of Pharmacy, Faculty
of Mathematics and Natural Sciences, P.O.Box 1068, Blindern, Oslo, 0316, Norway
http://dx.doi.org/10.1016/j.ijpharm.2014.06.016
0378-5173/ã 2014 Elsevier B.V. All rights reserved.Chitosan fulfils all the above mentioned criteria (Bernkop-
Schnürch and Dünnhaupt, 2012; Bhattarai et al., 2010).
Moreover, chitosan as mucoadhesive polymer is suited for
repeated adhesion, as it does not become inactivated after the
first contact with mucus; no reduction in its mucoadhesiveness
has been reported (Valenta, 2005). In respect to recurrence, it is
now clear that bacterial biofilms play an important role, as the
negatively charged polysaccharide matrix coats the bacteria in
the biofilm and restricts the penetration of antimicrobial in
deeper parts of biofilm. Recently, chitosan was proposed to be
able to disrupt bacterial biofilms in vaginal environment more
efficiently than other polymers (polycarbophil). Even more
importantly, its anti-biofilm effect was found to be pH-
independent (Kandimalla et al., 2013).
The mucoadhesiveness of chitosan-based delivery systems has
been studied in various routes of drug administration (das Neves
et al., 2011a; Gradauer et al., 2012; Sugihara et al., 2012; Takeuchi
et al., 2001; Takeuchi et al., 2005; Wang et al., 2011); however, its
potential in vaginal drug delivery was comparatively less studied
(Valenta, 2005; Bonferoni et al., 2008; Kast et al., 2002; Perioli
et al., 2008; Perioli et al., 2009; Berginc et al., 2014). Based on its
confirmed mucoadhesiveness, it is reasonable to expect that
chitosan-based delivery systems will be superior in vaginal drug
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(Meng et al., 2011).
The success of non-invasive drug delivery via vaginal mucosa
will be the result of the interplay between the local vaginal
environment, drug and physicochemical properties of drug carrier
(Berginc et al., 2014). However, the interaction between drug
delivery system and cervicovaginal mucus can affect the perfor-
mance of drug nanocarrier, as the carrier must migrate through the
vaginal or cervical fluid in order to deliver drug to the underlying
mucosal surface (das Neves et al., 2012; Vanic and Škalko-Basnet,
2013). Vaginal mucosal tissue has relatively low turnover, which
would be beneficial for prolonged residence time (Andrews et al.,
2009). Vaginal absorption of drugs occurs in two main steps,
namely the drug dissolution in vaginal lumen followed by the
membrane penetration (Hussain and Ahsan, 2005).
As a model drug we selected clotrimazole, often prescribed in
vulovaginal candidiasis. Its local therapy is recommended to
pregnant and breast-feeding patients, as well as to patients not
using reliable birth control methods, or planning to become
pregnant (das Neves et al., 2008).
2. Materials and methods
2.1. Materials
Lipoid S 100 (PC, soybean lecithin, >94% phosphatidylcholine)
was a generous gift from Lipoid GmbH, Ludwigshafen, Germany.
Chitosan, low molecular weight (Brookfield viscosity 20,000 cps,
degree of deacetylation (DD of 92%), acetonitrile (CHROMASOLV1
gradient grade), bovine serum albumin, clotrimazole, glycerol,
methanol CROMASOLV1, mucin from porcine stomach (type III,
bound sialic acid 0.5–1.5%, partially purified) and sodium chloride
were the products of Sigma–Aldrich, Chemie GmbH, Steinheim,
Germany. Acetic acid (glacial), anhydrous potassium phosphate
and sodium hydrogen phosphate were purchased from Merck
KGaA, Darmstadt, Germany. Calcium hydroxide, glucose, lactic
acid, potassium hydroxide, propylene glycol, sodium hydroxide
and urea were obtained from NMD, Oslo, Norway. Ammonium
acetate was the product of BHD Prolab, Leuven, Belgium.
2.2. Preparation of liposomes with clotrimazole
Liposomes were prepared by the method described earlier
(Berginc et al., 2014). In brief, clotrimazole (20 mg) and PC
(200 mg) were dissolved in methanol in a round bottom flask. The
solvent was evaporated using rotoevaporator system (Büchi
rotavapor R-124 with vacuum controller B-721, Büchi Vac1 V-
500, Büchi Labortechnik, Flawil, Switzerland) for at least 1 h at
50 mm Hg and 40 C. The remaining film was then re-suspended
in 10 mL of distilled water. If necessary, ultrasonic bath was used
to completely dislodge the film from the flask. Liposomal
suspensions were stored in the refrigerator (4–8 C) overnight
prior to further use.
2.3. Vesicle size reduction
Liposomes (4 ml) were transferred to a 10 mL beaker and placed
on ice bath. The needle probe tip of probe sonicator was placed in
the centre of the beaker containing liposomal suspension. The
sonicator (Ultrasonic processor 500 W, Sigma–Aldrich, St. Louis,
MO, USA) was set to 40% amplitude and the liposomes were
exposed to ultrasonic irradiation for 1, 2 or 2  2 min, respectively.
The sonicated liposomes were stored in the refrigerator for at least
6 h prior to further use.2.4. Particle size analysis
The particle size distributions of liposomes were determined by
photon correlation spectroscopy (Submicron particle sizer model
370, Nicomp, Santa Barbara, CA, USA). In order to avoid
interference from dust particles, the test tubes to be used for
the determination were filled with distilled water and sonicated
for 10 min in ultrasonic bath, then rinsed with filtered water (using
0.2 mm filter) prior to the experiments. Small aliquots of the
samples were diluted with the filtered water to obtain particle
intensity of approximately 200–350 kHz (di Cagno et al., 2011). All
formulations were prepared in a laminar airflow bench and
analyses run in vesicle mode and the intensity–weight distribution
at 23 C. Three parallels were determined (run time 10 min) for
each sample measurement.
2.5. Zeta potential determination
Zeta potential measurements were performed on a Malvern
Zetasizer Nano Z (Malvern, Oxford, UK). To ensure the validity of
the measurements, the instrument was calibrated throughout the
measurements using the Malvern zeta potential transfer standard
(50  5 mV). The liposomal suspensions were diluted in 1:40
ratio in filtrated water before measurements to achieve the proper
count rate. All measurements were performed at 23 C and the
results were expressed as the average of at least three independent
samples.
2.6. Entrapment efficiency determination
To separate free from liposomally entrapped drug, the sonicated
liposomes were ultracentrifuged (Beckman model L8-70M prepara-
tive ultracentrifuge with SW 60 Ti rotor, Beckman Instruments, Palo
Alto, CA, USA) for 30 min, at 10 C and 85,000 g. The pellet
(containing unentrapped drug and liposomes larger than
200 nm) was separated from the supernatant (smaller liposomes
containing clotrimazole), re-suspended in 500 mL of distilled water
and finally diluted to 2 mL with methanol. Drug content in both
supernatant and pellet was determined by the HPLC method. A
reversed phase column (XTerra1RP18 5 mm, 3.9  150 mm column,
Waters, Dublin, Ireland) installed in a Waters e2795 separations
module coupled with a Waters 2489 UV–vis detector was used in
the measurements. The mobile phase consisted of acetonitrile and
MilliQ water in a gradient starting at 30% acetonitrile (A), increasing
to 90% A over 10 min, then to 100% A after 11 min. The HPLC
measurements settings were as follows: flow rate 1 mL/min,
column temperature of 25 C, sample temperature 25 C, injection
volume 20 mL, run time 11 min and the detection wavelength
210 nm. The correlation coefficient was 0.9997 and the minimum
detectable amount of clotrimazole 0.5 mg/mL. The entrapment was
expressed as the amount of drug present in sonicated vesicles. The
measurements were performed in triplicates.
2.7. Phospholipid content
An enzymatic assay was used to determine the amount of lipid
present in liposomes in order to calculate the entrapment
efficiency. For this purpose a commercial test kit (Phospholipids
B; Wako Chemicals USA, Inc., Richmond, VA, USA) was applied in
the method described earlier (Basnet et al., 2012). Measurements
were performed in triplicates.
2.8. Coating of liposomes
The chitosan solutions (0.1, 0.3 and 0.6%, w/v) used for liposome
coating were prepared in 0.1% and 0.5% (v/v) glacial acetic acid,
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equal volume of liposomes free from unentrapped clotrimazole,
under controlled magnetic stirring at room temperature for 1 h,
followed by incubation in the refrigerator overnight. The rate of
stirring was kept constant for all preparations (Karn et al., 2011).
2.9. In vitro release study
Drug release was followed by the method described earlier
(Hurler et al., 2012). The Franz cell manual diffusion system (Perme
Gear Ink, Diffusion cells and Systems, Hellertown, USA) was
properly cleaned with methanol, demineralized water and distilled
water, respectively. The heating circulator (Julabo Laboratechnik,
F12-ED, Seelback, Germany) was set to 37 C. The acceptor
chamber (12 mL) was filled up with acetate buffer (pH 4.6, 77.1 g
of CH3COONH4, 70 mL of glacial acetic acid and distilled water up to
1000 mL). Cellophane membrane (Max Bringmann KG, Wendel-
stein, Germany) was pre-soaked in the same buffer. Liposomal
samples (both chitosan-coated and non-coated and sonicated for
2  2 min) or controls (clotrimazole in propylene glycol) were
added in the donor chamber and the system was properly sealed.
The drug content in all tested samples was determined (HPLC)
prior to the study and the volumes of formulations in donor
chambers normalized to assure the same drug amount. The
samples (500 ml) were collected after 1, 2, 3, 4, 8 and 24 h. The
samples were replaced by an equal volume of buffer upon removal
of sample from the acceptor chamber. The drug content was
determined by the HPLC method. The experiments were
performed in triplicates.
2.10. Preparation of vaginal tissue
The sheep vaginal tissue (from pregnant animals) was obtained
from the Laboratory Animal Centre, University of Oulu, Finland.
The vaginal tissue was carefully removed from the underlying
tissue and cleaned with the physiological solution (pH 7.4).
Adequate sized pieces were moisten by 0.9% (w/w) NaCl and
packed in clinging film, and frozen (20 C). They were left to
defrost at room temperature for at least 2 h prior to experiments.
The thickness of the tissue was determined to be ranging from 900
to 1140 mm. It was earlier confirmed that no significant differences
were observed in using fresh or snap-frozen tissue samples (Sassi
et al., 2004). We have earlier also compared the barrier properties
of the fresh vaginal tissue and frozen (20 C) and thawed tissue
(both animal skin and vaginal tissue) and have not observed any
difference in the properties.
2.11. Ex vivo penetration study
The defrosted vaginal tissue was cut to fit the Franz diffusion
cells surface (1.77 cm2). The acceptor chamber was filled up with
phosphate buffer (pH 7.4, 8 g/L NaCl, 0.19 g/L KH2PO4, and 2.38 g/L
Na2HPO4) and the vaginal tissue fixed between donor and acceptor
chamber. Samples (600 mL) were added into the donor cells and
the system was properly sealed. The amount of the drug in each cell
was the same, as confirmed by the HPLC analysis. Samples of
500 mL were collected at 1, 2, 3, 4, 8 and 24 h and replaced with an
equal amount of buffer. Drug content was determined by the HPLC
method. The measurements were performed in triplicates.
2.12. In vitro mucin-binding test
The mucoadhesion was measured by determining the binding
of liposomes to pig mucin. Liposomes (1 mL) were mixed with
equal volume of pig mucin (PM) suspension (400 mg/mL) in 0.05 M
PBS (pH 7.4) and incubated at room temperature for 2 h, followedby ultracentrifugation for 1 h, at 10 C at 216,000 g (Optima LE-80;
Beckman Instruments, Palo Alto, USA). Aliquots of 200 mL (4 from
each sample) of the supernatants (free PM) were transferred to a
microtitre plate (Costar1UV 96-well plate with UV transparent flat
bottom, Acrylic, Costar1, Corning, NY, USA) and measured
spectroscopically at 251 nm (Microtitre plate reader; Spectra
Max 190 Microplate, Spectrophotometer Molecular devices,
Sunnyvale, CA, USA). The PM binding efficiency was calculated
according to Naderkhani et al. (2014).
2.13. Statistical evaluation
The student's t-test was used for comparison of two means. A
significance level of p < 0.05 was considered to be appropriate.
3. Results and discussion
In order to achieve optimal therapeutic outcome, the delivery
system is expected to provide a sufficient amount of the active
ingredient (in our case clotrimazole) at the desired site of action
(vaginal mucosal tissue) for a sufficiently long period of time to
enable drug to perform its therapeutic action. Therefore, in the first
step in optimization of chitosan-coated liposomes for topical
vaginal delivery, we were focusing on the relationship between
encapsulation yields vs particle size. Smaller particles are expected
to provide larger surface area, however those particles carry less
clotrimazole load, whereas larger particles will incorporate more
of the drug, but will provide smaller contact surface for possible
mucoadhesion.
3.1. Liposomal characteristics
Liposomes have been studied as drug delivery systems for
almost 5 decades. A number of liposomes-based products are on
the market and many more are in pipelines (Allen and Cullis, 2013).
We have previously reported on the potential of liposomes to
enhance the anti-inflammatory properties of associated curcumin
destined for vaginal therapy (Basnet et al., 2012). Guided by those
promising results, we selected liposomes as carrier for clotrima-
zole and used chitosan-coating to (i) assure prolonged and
controlled release of clotrimazole and (ii) assure its retention at
vaginal site, without significant penetration through the vaginal
tissue.
Size and size distribution of liposomes are important character-
istics of liposomes destined for topical drug delivery. The effect of
liposomal size on the efficacy of liposomal delivery to skin is rather
well studied (Cevc, 2004); however, relatively little is known about
the effect of vesicle size on the delivery of drugs intended for
mucosal targeting at vaginal site. Takeuchi et al. (2001) have found
that the amount of liposomes penetrating into the intestinal
mucous layer increased when the size of the liposomes was
reduced to approximately 100 nm for both non- and chitosan-
coated liposomes. In previous experiments (Berginc et al., 2012)
we observed that curcumin in smaller vesicles penetrated less into
the upper layers of vaginal tissue as compared to curcumin in
mulitilammelar vesicles. Both types of liposomes exhibited better
tissue retention as compared to curcumin in solution form.
Similarly, polymer nanoparticles smaller than 200 nm were
reported to successfully deliver small-interfering RNA and
provided sustained gene silencing throughout the female repro-
ductive tract for at least 14 days (Woodrow et al., 2009).
The particle size shown in Table 1 indicates that the liposomes
sonicated for 2  2 min were in the desired size range. Liposomal
dispersions exhibited two distinguished peaks in distributions,
indicating bimodal distribution and rather high polydispersity
Table 2


















– 107  3 54  3 27  3 46  3 0.34 1.6  0.2
0.1 135  21 53  6 42  9 45  5 0.29 25.9  4.0
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0.6 190  8 58  6 54  2 42  6 0.29 43.8  3.3
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1 317  47 56.8 40  5 41.0 0.58 23.2  2.5
2 234  31 53.9 36  5 43.8 0.46 25.0  0.5
2  2 111  16 83.1 29  4 16.9 0.46 16.5  4.5
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index values decreased, as expected (Table 1).
We tried to minimize the exposure of liposomes to the
sonication force, as it is known that extensive sonication can lead
to the release of originally incorporated drug and lipid degradation
(di Cagno et al., 2011).
Due to highly lipophilic nature of clotrimazole (log P of 3.5),
clotrimazole was dissolved in the organic solvent together with
lipid during the preparation of liposomes and was expected to
incorporate itself within lipid bilayers of liposomes. We observed
similar entrapment efficiencies for liposomes sonicated for 1 and
2 min, and the loss of originally entrapped clotrimazole was
remarkable only after sonication for 2  2 min, resulting in smaller
liposomes (Table 1). In comparison to literature data, our
entrapment (up to 22 mg clotrimazole/mg lipid) was found to be
lower; however, none of the published articles describes the use of
the same liposome preparation method and phospholipid compo-
sition. Although Ning et al. (2005) reported a very high entrapment
of clotrimazole (over 90%) using the film method in preparation of
liposomes, they used dialysis to separate unentrapped from
liposomal drug. The fact that clotrimazole has aqueous solubility
of only 5.5 mmol/L (molecular weight 344) (Bilensoy et al., 2006),
and that no data is available on whether or not the sink conditions
were assured in the experimental set up of Ning et al. (2005), it
might be possible that part of the drug was accumulated in the
dialysis-tube in a form of precipitates, falsely contributing to high
entrapment values. Liposomes prepared by the proliposome and
polyol dilution methods were reported to incorporate more
clotrimazole (Pavelic et al., 1999, 2005); however, the methods of
preparations differed from the method used in our experiments,
and, more importantly, the vesicle size was larger than in our case.
Proliposome method is known to yield multilamellar liposomes
thus enabling high incorporation of lipophilic drug (Pavelic et al.,
1999). An additional difference between the previous and current
experiments was the liposomal composition (Pavelic et al., 2005).
We choose to prepare liposomes from a simple lipid mixture to be
able to follow the effect of chitosan coating in a rather straightfor-
ward manner, avoiding the interference of possible ionic inter-
actions between lipid and chitosan and consequently mucin.
The coating of liposomes is expected to result in an increase in
their original size (Filipovic-Gr9cic et al., 2001; Karn et al., 2011).
Although the entrapment of clotrimazole was lower than we have
desired, considering that the obtained vesicle size was in the
optimal range for the purpose of development of mucoadhesive
liposomal delivery system, we proceeded with coating of those
vesicles. Prolonged retention time would be a rationale for
lowering the dose needed to induce antifungal effect; therefore
lower drug load should not limit the applicability of the system.
3.2. Coating of liposomes
It is well established that the polymer concentration signifi-
cantly influences the strength of mucoadhesion. Moreover, theoptimal polymer concentration depends on the physical state of
the delivery system (Andrews et al., 2009) and, in the case of
coated liposomes; the liquid nature of the system needs to be taken
into consideration. Therefore, we have used three different
concentrations in the coating of liposomes, all resulting in liquid
formulations. The coating resulted in an increase in particle size
(Table 2), in agreement with the results reported by Karn et al.
(2011) and Gradauer et al. (2012). The coating of liposomes with
chitosan also resulted in an increase of liposome zeta potential
(Table 2) in agreement with Berginc et al. (2014). Moreover, the pH
of liposomal suspensions changed upon coating; non-coated
liposomal suspensions had a pH of 6.0 whereas 0.1, 0.3 and 0.6%
coated liposomal suspensions had a pH of 4.12, 4.02 and 4.07,
respectively. This would represent additional advantage of
chitosan-coated liposomes; it is well known that C. albicans
adheres to vaginal tissue with higher affinity at pH 6 than at pH 4
and that acidic formulations also restore the physiological acid pH
of vagina (Chang et al., 2002).
It was previously reported that the amount of polymer used for
coating of nanoparticles and found on vesicle surface was similar
regardless of the molecular weight of chitosan used (Llabot et al.,
2011). However, nanoparticles coated with low molecular weight
chitosan where found to be more bioadhesive than those coated
with high molecular weight chitosan. This could be explained by
the interpenetration mechanisms with the mucin chains, as it is
known that long polymer chains reduce the interpenetration,
reducing the bioadhesive strength (Llabot, et al., 2011). This was
the reason why we have selected low molecular weight chitosan as
a coating material.
Although there is no consensus on the optimal size range of
nanocarriers expected to penetrate mucus layer, it was suggested
that the nanocarriers in the size range of 200–500 nm are superior
to both much smaller and also larger nanosystems (das Neves et al.,
2011b). Takeuchi et al. (2005) confirmed the superiority of
nanosize chitosan-coated liposomes in prolonging the retention
time in the intestinal mucosa as compared to larger vesicles.
However, the vaginal mucosa has unique features which make
direct translation of the results rather difficult.
Regarding the optimal size, it is also important to consider that
some of the particles tend to agglomerate, and that agglomerates
behave in a different manner than single particles (das Nevas et al.,
2011a). We have tested our liposomes for one month stability (at
4 C) and have not observed a significant increase in the original
size of chitosan-coated vesicles (data not shown). It can be
hypothesized that the chitosan-coating is working as a stabilizer by
prohibiting agglomeration of the liposomes, even though the
chitosan is not bound to the lipid surface either by covalent or ionic
bonds. Although liposomes made of phosphatidylcholine have no
surface charge, the electrostatically driven binding of chitosan to
the lipid membrane is energetically favoured, even for neutral
liposomes, leading to further stabilization of the vesicle suspen-
sion, as reported recently (Mertins et al., 2010; Mertins and
Dimova, 2011).
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There are several means to achieve the prolonged release of
drugs destined for vaginal administration. Most of the approaches
rely on the use of polymer in a form of hydrogel, to assure both
prolonged release and intimate contact between drug and vaginal
mucosa, simultaneously using liposomes as solubilizers for poorly
soluble drugs (Pavelic et al., 2005). Other approaches use the
complexation of drug with cyclodextrine, followed by incorpo-
ration of a complex in a hydrogel, such as for example pluronic
thermosensitive gel, exhibiting prolonged release of clotrimazole
when the drug was complexed with b-cyclodextrine prior to
inclusion into the hydrogels (Bilensoy et al., 2006).
We have followed the release of liposomally-associated
clotrimazole (Fig. 1) in comparison to clotrimazole in a free form
(propylene glycol as vehicle). All liposomal formulations exhibited
prolonged release as compared to free drug (control). All
formulations, even the control, also failed to release all of the
incorporated clotrimazole, which may be explained by the fact that
clotrimazole, a very hydrophobic molecule, has very limited
solubility in water. In the case of the control (propylene glycol), an
osmotic effect was observed drawing water from the acceptor
medium into the sample in donor chamber. As a consequence,
clotrimazole started to precipitate (in donor chamber) when a
critical amount of drug dissolved in propylene glycol is mixed with
water. Therefore, we assume that it would be necessary to add
some sort of solubilizing agent into the acceptor medium (acceptor
chamber) to secure sink conditions. The limitation of Franz
diffusion system is the limited volume which can be used in the
acceptor chamber, causing the problems for the poorly soluble
drugs. However, we could detect the differences between control
(free drug) and the drug released from liposomes. Although we
have expected the slowest release from chitosan-coated lip-
osomes, interestingly, the slowest release of the drug was
perceived from non-coated (plain) liposomes (p < 0.05). Non-
coated liposomes act as solubilizer for clotrimazole in the lipid
membrane and the drug only diffuses from the lipid membrane as
liposomes become leaky, if not coated. It seems that the
partitioning of clotrimazole between outer aqueous medium
and liposomal bilayers is in favour of liposomal bilayers, whereas
in coated liposomes, the release is supported by the presence of
chitosan coating. We have also observed the difference in the
release from liposomes coated with three different concentrations
of chitosan; those coated with higher concentration of chitosan
exhibited more pronounced sustained release, however not on a
significant level. Chitosan is hydrophilic in nature and makes the
surface of liposomes less hydrophobic, as in chitosan-coated
liposomes. The thicker coatings (0.3 and 0.6%, w/v, respectively)Fig. 1. In vitro release of clotrimazole from coated and non-coated liposomes (n = 3).
The concentration of clotrimazole in all formulations was the same. Control (*) contained
the same concentration of clotrimazole as in coated liposomes.will cause the diffusion obstacle for the drug released from the
surface, resulting in the slower release. Berginc et al. (2014)
reported that increasing the amount of chitosan in the liposomal
coating had no beneficial effect on the permeability of liposomally-
associated curcumin. This is very interesting, and could be relevant
for different types of mucoadhesive coatings on the surface of
various nanoparticles and requires further studies. This finding is
in agreement with report by Fang et al. (2001) who proposed that
even the lowest chitosan mole fraction is able to reduce the
cooperative unit of the DPPC bilayer and lead to certain degree of
membrane bilayer perturbation. Reduction of pH increased the
number of protonated amines on the chitosan backbone and
caused further disruption on the membrane organization. Al-
though we have used different lipid in our experiments, the
interactions between chitosan and polar head of phospholipids are
well established (Mertins et al., 2010, 2011). Whether the
observation we made for chitosan-coated liposomes incorporating
clotrimazole would also apply for liposomally-entrapped hydro-
philic drugs and for liposomes of various phospholipid composi-
tions remains to be determined.
3.4. Ex vivo penetration of liposomally-associated clotrimazole
The mucoadhesive properties of chitosan are mostly result of its
cationic character. Mucoadhesion of chitosan-based delivery
systems can therefore be achieved through ionic interactions
between the cationic primary amino groups of chitosan and the
anionic substructures of the mucus. In addition, the hydrophobic
interactions might contribute to its mucoadhesive properties
(Bernkop-Schnürch and Dünnhaupt 2012). Although thiolated
chitosans have stronger mucoadhesive properties than non-
modified chitosan, their compatibility with vaginal environment
remains to be proven, and we have therefore opted for non-
modified chitosan as a coating material. Chitosans of high degree of
deacetylation and of a high molecular mass were reported to cause
an increase in the epithelial permeability (Bernkop-Schnürch and
Dünnhaupt, 2012), which needs to be taken into consideration
when choosing the type of chitosan for the coating of liposomes
intended for administration into pregnant patients, and was the
reason that we selected low molecular weight chitosan. We are
currently evaluating the system in the in vivo conditions in
pregnant sheep to confirm the safety and non-irritability of the
system, as it is well-known that vaginal irritation can lead to
increased susceptibility to foreign pathogens and inflammation.
Mucus is a viscous coating on many epithelial surfaces and
consists mainly of water (up to 95% weight), inorganic salts,
carbohydrates, lipids and glycoproteins, termed mucins. Mucins
are hydrosoluble and responsible for the gel-like properties of the clotrimazole in propylene glycol; non-coated liposomes (**) were diluted to obtain
Fig. 2. Ex vivo penetration studies (24 h) in vaginal tissue (n = 3).
The concentration of clotrimazole was the same in all formulations. Control
contained clotrimazole in propylene glycol; non-coated liposomes were diluted to
obtain the same concentration of clotrimazole as in coated liposomes. Liposomal
formulations assured significantly less (p < 0.01) drug penetration as compared to
the control.
Fig. 3. Mucin-binding (PM) efficacy for non-coated and chitosan-coated liposomes
(n = 3).
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the wetting and swelling of polymer should enable an intimate
contact with the mucosal tissue, followed by interpenetration of
the polymer chains and entanglement between the polymer and
mucin chains. Chitosan exhibits strong bioadhesive properties
through the electrostatic interactions with sialic groups in mucins
of the mucosal layer. The high positive charge density of chitosan
enhances its mucoadhesiveness (Meng et al., 2011). It is also
important to consider the concentration of liposomes applied to
vaginal tissue, as this may affect the normal structure of mucus and
cause the collapsing of mucin fibres (das Neves et al., 2011b). The
concentration of liposomes used in our experiments was low and
not expected to cause changes in mucosal structure and was
considered to be safe. However, it remains to be evaluated in the in
vivo studies in suitable animal model.
Although the mucoadhesive behaviour of bulk material such as
polymer-based hydrogels made of chitosan for example is well
characterized, rather little is known about the behaviour of
chitosan at the nanoscale (das Neves et al., 2011b). We have
previously confirmed the bioadhesion potential of chitosan-based
hydrogels onto the skin (Hurler and Škalko-Basnet, 2012);
however, the bioadhesiveness of chitosan-coated liposomes in
nanosize range cannot be directly compared to hydrogels.
We have used the vaginal tissues of pregnant sheep to mimic
closer the in vivo evaluation of our formulation in pregnant
animals. The results presented in Fig. 2 indicate that liposomes are
able to retain associated clotrimazole on the vaginal tissue and in
the tissue, thus preventing undesired penetration through the
vaginal tissue. This is of great importance considering clotrimazole
therapy in pregnant patients. The free drug, a form of propylene
glycol solution, penetrated through vaginal tissue in remarkable
manner (almost 40% after 24 h), whereas the liposomally-
associated drug penetrated to significantly lower extent (p < 0.01).
We are aware that propylene glycol is a known skin penetration
enhancer and acts as a carrier-solvent for poorly soluble substances
such as clotrimazole. Moreover, propylene glycol may induce the
osmotic effects which result in the changed barrier properties of
the tissue. However, due to a very low solubility of clotrimazole,
the choice of a solvent which we could use to prepare clotrimazole
solution was very limited. Most of the other solvents are expected
to directly damage the barrier properties of the vaginal tissue,
resulting in the even higher penetration.
In respect to the drug retention on and within vaginal tissue, it
appears that liposomes coated with 0.1% chitosan solution
exhibited lowest penetration of clotrimazole and highest amount
of clotrimazole retained on top of the tissue (Fig. 2), both in
comparison to plain, non-coated liposomes and liposomes coatedwith different polymer concentrations. One has to consider that
the increased retention time on the target site would outweigh
more sustained release from non-coated liposomes (Fig. 1), as
reported for mucoadhesive liposomes incorporating curcumin
(Berginc et al., 2014).
The vulovaginal candidosis is characterized by the infection
reaching the deeper epithelial layers (das Nevas et al., 2008); thus
prolonged retention time on the vaginal mucus would be
beneficial. To confirm that chitosan coating on liposomal surface
is available for close interaction with mucin, we tested non-coated
and coated liposomes for mucin-binding potential (Fig. 3). The
results clearly indicate (p < 0.01) that liposomes coated with 0.1%
polymer concentration exhibit superior interaction with mucin in
comparison to all other formulations. This indicates that they
exhibit potential to retain at the vaginal site. This type of liposomes
may improve the effectiveness of model drug, yet prevent the
undesired systemic absorption.
It is expected that lipophilic substances/drugs are absorbed
from vagina as administration site through the transcellular
pathway (Sassi et al., 2004). The passive diffusion was found to
be the main mechanism of curcumin penetration into vaginal
mucosa when liposomally-associated curcumin was tested in
the ex vivo conditions. Our current findings are in full
agreement. Depending on the liposomal size, the concentration
of curcumin in different layers of vaginal tissue was found to be
significantly higher as compared to concentration of curcumin
applied in a form of solution. The permeability from 0.6%
chitosan-coated liposomes was found to be similar or even lower
than from 0.1% coated liposomes when tested in artificial and
isolated bovine mucus. This can be explained by the fact that an
increase in the liposomal size, as well as changes in zeta
potential, lead to the major part of the polymer being hindered
in the deeper layers and unavailable for immediate adhesion.
Only when the uppermost polymer sheets of higher polymer
concentrations coatings are removed by erosion or by detach-
ment from mucus, more chitosan becomes available for
adhesion. This was proposed as an explanation for the
superiority of liposomes coated with lower concentration of
polymer (Berginc et al., 2014). In addition, liposomal curcumin
administered vaginally exhibited negligible potential for system-
ic absorption, which would greatly support its administration in
pregnant patients (Berginc et al., 2012) in agreement with our
findings.
Currently, there is a vivid discussion in the field of vaginal drug
delivery whether the mucoadhesiveness of delivery system is
advantageous for improved drug therapy or rather disadvanta-
geous (das Neves et al., 2011a). The physical properties of mucus
are complex and often described as non-Newtonian behaviour
with properties between those of a viscous liquid and an elastic
solid. In women with bacterial vaginosis, the viscosity of vaginal
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barrier properties of vaginal mucus (Lai et al., 2009). Nevertheless,
there is a consensus that the nanocarrier should first be retained at
the vaginal site to increase the residence time and avoid vaginal
leakage, and subsequently migrate through mucus towards the
mucosal surface (das Neves et al., 2012). Antifungal agents used to
treat vaginal candidosis need to penetrate deep into the epithelium
to reach invasive Candida hyphae and exert a local antifungal
action (das Neves et al., 2008). One approach to achieve this
purpose has been recently suggested by our groups by using
deformable propylene glycol liposomes (Vanic et al., 2014).
Another approach is based on applying chitosan-based mucoad-
hesive liposomes developed in this study.
Our findings clearly indicate that liposomes are a suitable
drug delivery system in respect to both prolonged release and
limited tissue penetration. Liposomes are able to assure
sustained release of associated drug either with or without
chitosan coating. However, coated liposomes are expected to
prolong the residence time in the vaginal cavity in the in vivo
conditions and are therefore, considered to be superior. The next
step involves the determination of bioadhesiveness of the
system by the modified method originally developed for skin
(Hurler et al., 2012).
We are aware of a need to address current limitations of
experimental set up, such as that our experiments were performed
on the vaginal tissue in the absence of cervicovaginal fluid. The
reason that we did not use cervicovaginal fluid surrogate, is that it
was reported that differences between the surrogate and native
mucus may be noticeable. We also did not vary the pH of the donor
medium, although it is known that the pH is affecting the transport
across mucus (das Neves et al., 2012). The effect of semen and the
changes in vaginal pH related to age and disease conditions remain
to be evaluated.
4. Conclusions
Chitosan-coated liposomes were shown to exhibit prolonged
release of associated clotrimazole. The penetration of liposomally-
associated clotrimazole through the vaginal tissue was reduced as
compared to non-coated liposomes, an important fact regarding
system's potential in topical vaginal therapy, especially in pregnant
patients. We are currently evaluating the system in the in vivo
conditions in pregnant sheep to confirm the safety and non-
irritability of the system as it is well-known that vaginal irritation
can lead to increased susceptibility to foreign pathogens and
inflammation.
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Vaginal infectionsResveratrol (RES), chemically known as 3,5,4′-trihydroxy-trans-stilbene, is a promising multi-targeted anti-
oxidative and anti-inflammatory natural polyphenol. Preclinical studies showed its biological activities against
the pathogens of sexually transmitted diseases causing vaginal inflammation and infections. Due to its low solu-
bility and poor bioavailability, the optimal therapeutic uses are limited. Therefore, a clinically acceptable topical
vaginal formulation of RES exhibiting optimal therapeutic effects is highly desirable. For this purpose, we pre-
pared and optimized chitosan-coated liposomes with RES. The coated vesicles (mean diameter 200 nm)
entrapped up to 77% of RES, a sufficient load to assure required therapeutic outcome. In vitro drug release
study showed the ability of liposomes to provide sustained release of RES. In vitro anti-oxidative activities of
RES, namely DPPH and ABTS•+ radicals scavenging assays, confirmed RES to be as potent as standard anti-
oxidants, vitamins C and E. The anti-oxidative activities of RES and its corresponding liposomal formulation
were also compared by measuring enhanced superoxide dismutase (SOD) activities in lipopolysaccharide
(LPS)-induced J774A.1 cells. In vitro anti-inflammatory activities were compared by measuring nitric oxide
(NO), tumor necrosis factor (TNF)-α and interleukin (IL)-1β production in LPS-induced J774A.1 cells. Liposomal
RES was found to exhibit stronger anti-oxidative and anti-inflammatory activities than RES solution.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Resveratrol (RES), a common natural compound produced by sever-
al plants in response to pathogenic infection (Houille et al., 2014), iszothiazoline)-6-sulfonic acid
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raholmen),
charya@uit.no (G. Acharya),identified chemically as 3,5,4′-trihydroxy-trans-stilbene. RES and its de-
rivatives were reported to exhibit fungicidal and anti-microbial activi-
ties (Chan, 2002; Baur and Sinclair, 2006; Adrian and Jeandet, 2012;
Houille et al., 2014). It also showed anti-viral effect (Docherty et al.,
2005). In addition to this, diverse pharmacological activities such as
anti-oxidative, anti-inflammatory, neuro-protective, anti-aging, anti-
cancer and cardio-protective effects of RES have been reported which
can carry potential therapeutic application to humans (Bhat et al.,
2001; Smoliga et al., 2011; Vang et al., 2011; Lu et al., 2013). Due to
the multi-targeted microbicide activities and significantly low toxic
effects, RES might be the potential candidate in safe topical treatment
of vaginal inflammation and infection especially in pregnant women.
The vaginal environment and structure are highly vulnerable towards
the pathogens such as various bacteria, fungi, viruses or protozoa
(Trichomonas) which cause vaginal inflammation and infection and
are often transmitted easily during sexual intercourse. Contamination
and rapid growth of these pathogens lead not only to inflammation
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human simplex virus type 2 (HSV-2) and human papilloma virus (HPV)
infections (Nikolic and Piguet, 2010). Therefore the understanding on
the cross-links between various diseases and microbicides together
with the link between HPV and cervical cancer was recognized by the
award of the 2008 Physiology and Medicine Nobel Prize (Abbott and
Brumfiel, 2008). Particularly, it is interesting that RES uses different
mechanisms to induce cell death in cervical cancer cell lines (Garcia-
Zepeda et al., 2013). In addition, pregnant women are vulnerable to
vaginal infection because of the reduced T-helper cell type 1 (TH1) ac-
tivities due to the development of protectivemode towards the growing
fetus. If they are not treated in time, the pregnancy might result in im-
paired fetal growth and development or even termination. Although
anti-microbial agents are commonly used in the treatment of pathogen-
ic vaginal infection, contemporary normal course of anti-microbial
therapy cannot be applied during pregnancy. Moreover, the problem
of anti-microbial resistance such as the one linked to metronidazole
(MDZ) and other 5-nitroimidazoles (tinidazole, ornidazole, and
secnidazole) used against trichomoniasis needs to be taken into con-
sideration (van de Wijgert and Shattock, 2007).
Regarding the pathogen resistance and serious side effects linked to
current anti-microbial options in vaginal therapy, especially in pregnant
patients, a multi-targeted, less toxic and potential candidate, such as
RES could be an ideal molecule. However, due to its low solubility and
poor bioavailability, the possible clinical uses against vaginal inflamma-
tion and infection remain limited. Clinically applicable and safe formula-
tion of RES assuring its optimal therapeutic value in the treatment of
vaginal inflammation and infection in pregnancy is needed. By applying
the chitosan-coated liposomal carrier for RES, we aimed to utilize the
ability of chitosan not only asmicrobicide target but also to disrupt bac-
terial biofilms, which is of great importance in the treatment of vaginal
bacterial inflammation and infections (Kandimalla et al., 2013). This
paper describes the nanomedicine-based topical formulation of liposo-
mal RES targeted to vaginal inflammation and infection. In vitro anti-
oxidative and anti-inflammatory effects of free RES were compared
with that of the corresponding liposomal formulation.
2. Materials and methods
2.1. Materials
Lipoid S 100 (PC, N94% phosphatidylcholine) was a gift from Lipoid
GmbH, Ludwigshafen, Germany. Vitamin C (ascorbic acid), chitosan
[low MW, Brookfield viscosity 20.000 cps, degree of deacetylation
(DD) of 92], 1,1-diphenyl-2-picrylhydrazyl (DPPH),mucin fromporcine
stomach (type III, bound sialic acid 0.5%–1.5%, partially purified), phos-
phorus standard solution (0.65mM), sodium chloride, resveratrol (RES:
3,5,4′-trihydroxy-trans-stilbene, purity ≥ 99%), vitamin E, 2,2′-azino-
bis(3-ethyl benzothiazoline)-6-sulfonic acid diammonium salt (ABTS)
and potassium peroxodisulphate were the products of Sigma-Aldrich,
Chemie GmbH, Steinheim, Germany. Acetic acid (glacial), anhydrous
potassium phosphate, and sodium hydrogen phosphate were pur-
chased from Merck KGaA, Darmstadt, Germany. Ammonium acetate
was obtained from BHD Prolab, Leuven, Belgium. Cibacron brilliant red
3B-A was purchased from Santa Cruz Biotech, Dallas, TX, USA. Glycine
hydrochloride Plusone® was obtained from Pharmacia Biotec, Upp-
sala, Sweden. Dulbecco's modified eagle medium (DMEM), trypsin–
ethylenediaminetetraacetic acid, lipopolysaccharide (LPS; Escherichia
coli, 055:B5), L-nitro-arginine methyl ester (L-NAME), sulfanilamide,
naphthylethylenediamine dihydrochloride, and phosphoric acid were
purchased from Sigma Life Science (Sigma–Aldrich Norway AS, Oslo).
Assay kit for SOD activity measurement was from Abnova GmbH
EMBLEM, Heidelberg, Germany, and TNF-α, and IL-1β measured
spectrophotometrically with the assay kits were from Cell Biolabs,
Inc., San Diego, CA, USA. All chemicals and solvents usedwere of analyt-
ical grade.2.2. Cell culture
Murinemacrophage, J774A.1 (ATCC® TIB67™) cells were purchased
fromATCC and used in the in vitro anti-oxidative and anti-inflammatory
studies. Cells (1 × 105 cells/ml) were cultured in 24-well plates with
DMEMmedium containing glutamine and 10% calf serumby incubating
at 37 °C in 5% CO2 for 24 h to stabilize and adhere on the plate. After 24 h
the cell medium was replaced with the LPS (1 μg/ml) and/or test sam-
ples (RES/corresponding liposomal formulations) containing medium.
The effects of the test samples on the LPS-induced pro-inflammatory
cytokines (TNF-α, IL-1β) and NO expressed in the medium and SOD
activity were measured after 24 h according to the instruction provided
in the commercial kits.
2.3. Preparation of stock solutions and application to cells
Stock solutions (10 mg/ml) of RES and vitamin E were prepared by
dissolving with dimethyl sulfoxide (DMSO). They were diluted with
DMEM medium to the desired concentration before the treatment
with the cells. In case of DMSO solution (for vitamin E and RES), maxi-
mum concentrations of DMSO were not more than 0.2% (v/v). All
other sampleswere prepared andwith themediumand applied directly
into the cells.
2.4. Anti-oxidative assays
2.4.1. Measurement of DPPH radical scavenging activity
Effect of RES on DPPH free radical was determined by the similar
method as reported previously (Basnet et al., 2012). In brief, DPPH solu-
tion (60 μM, 0.3ml) in ethanol wasmixedwith an equal volume of each
sample solution (1, 5, 10 or 20 μg/ml as thefinal concentrations). The re-
actionmixturewas thoroughlymixed and kept in the dark for 30min at
room temperature. The anti-oxidative activity of RES was expressed by
measuring the decreased absorbance intensity at 519 nmwith UV spec-
trophotometer (Agilent Technologies, Santa Clara, CA, USA) using fol-
lowing formula: Radical scavenging activity (%) = 100 × (A − B) / A,
where A is the control (absorbance of DPPH radicals without sample)
and B is the absorbance of radicals after reacting with the sample. The
anti-oxidative activity of RES was also compared to that of vitamin C
and vitamin E under the same experimental conditions. The results
are expressed as mean ± S.D. of three experiments.
2.4.2. Measurement of ABTS•+ radical scavenging activity
ABTS•+ radicals were generated by mixing equal volumes (3 ml)
from each of the stock solutions of ABTS (7.4 μM) and potassium
peroxodisulphate (2.6 μM) in distilled water. The reaction mixture
was allowed to stabilize for 3 h at room temperature and then diluted
with ethanol to 100 ml as the ABTS•+ radicals working solution. The
green colour ABTS•+ radicals working solution (0.3 ml) was mixed
with an equal volume of sample solutions at the 1, 5, 10 and 20 μg/ml
concentration. After mixing, it was kept in the dark at room tempera-
ture. After 30 min, optical density was measured with UV spectropho-
tometer at 731 nm. As the number of ABTS•+ radicals decreases, the
intensity of green colour reduces. Results were expressed as described
for DPPH radical assay. The anti-oxidative activity of RES was compared
to that of the vitamin C and vitamin E under the same experimental
conditions.
2.5. Preparation of liposomes
Liposomes were prepared by the film hydration method as de-
scribed earlier (Jøraholmen et al., 2014). Briefly, RES (10 or 20 mg)
was dissolved in methanol and mixed with phosphatidylcoline (PC,
200 or 400 mg) in methanol and solvents were evaporated on Büchi
rotavapor R-124 (with vacuum controller B-721, Büchi Vac® V-500,
Büchi Labortechnik, Flawil, Switzerland) for at least 3 h at 50 mm Hg
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(10 ml). Throughout the preparation RES solution was kept protected
from light. Empty liposomes were prepared by similar method. Liposo-
mal suspensions were stored in refrigerator (4–8 °C) for at least 12 h
prior to further use.
Liposomal size was reduced through the extrusion through polycar-
bonate membranes with defined pore sizes (Nuclepore Track-Etch
Membran, Whatman House, Maidstone, UK). The extrusion was per-
formed stepwise through the 0.8, 0.4 and 0.2 μm pore size filters and 5
extrusions were executed for each step.
2.6. Coating of liposomes
Coating of liposomeswas performed in the presence of unentrapped
RES. In brief, chitosan solutions (0.1, 0.3 and 0.6%,w/v)were prepared in
0.1% and0.5% (v/v) glacial acetic acid, respectively. The chitosan solution
(2ml) was added dropwise to an equal volume of liposomal dispersion
under controlledmagnetic stirring at room temperature for 1 h, follow-
ed by the incubation in the refrigerator (4–8 °C) overnight. The rate of
stirring was kept constant for all preparations (Jøraholmen et al., 2014).
2.7. Characterization of liposomes
2.7.1. Size
The liposomal size distributions were determined by photon corre-
lation spectroscopy (Submicron particle sizer model 370, Nicomp,
Santa Barbara, CA, USA) as reported previously (Jøraholmen et al.,
2014). The particle intensity was approximately 250–350 kHz the anal-
yses run in vesicle mode and intensity-weight distribution. Three paral-
lels (with a run time of 10 min for each parallel) were determined for
each sample measurement.
2.7.2. Zeta potential measurements
Zeta potentialmeasurementswere performed on aMalvern Zetasizer
Nano ZS (Malvern, Oxford, UK) according to Jøraholmen et al. (2014). To
assure accuracy, the instrumentwas calibrated throughout themeasure-
ments using the Malvern Zeta Potential Transfer Standard (−50 ±
5 mV). Measurement cell (DTS1060) was cleaned with ethanol and
filtrated water (0.2 μm), respectively, prior to loading of sample. The li-
posomal suspensions were diluted with filtrated water to appropriate
concentrations (typically 1:20) before the measurements, to achieve
the proper count rate. All measurements were performed at 25 °C and
three parallels were measured.
2.7.3. Entrapment efficiency determination
RES liposomes (2 ml) were dialyzed (Mw cutoff: 12–14,000 Da,
Medicell International Ltd., London, UK) against distilled water
(500 ml) for 4 h at room temperature. The volume of medium was ad-
justed to assure the solubility of RES. Aliquots of sample and medium
were diluted in methanol, and the amount of liposome-associated RES
was determined by UV spectrophotometer (Agilent Technologies,
Santa Clara, CA, USA) at 306 nm. The correlation coefficient for standard
curve was 0.9958 and the minimum detectable amount for RES was 1
μg/ml.
2.7.4. Phospholipid assay
The content of PCwasmeasured using themodified Bartlett method
as reported previously (Andersen et al., 2015). Phospholipid content
was measured by UV spectrophotometer (Agilent Technologies, Santa
Clara, CA, USA) at 830 nm. The phosphorous standard solution was
used to prepare standard curve in concentration range of 1–10 μg/ml.
2.8. Chitosan determination
The surface-available chitosan was determined by a modified color-
imetric method (Andersen et al., 2015). In brief, glycine buffer (pH 3.2)was prepared by dissolving glycine (1.87 g) and NaCl (1.46 g) in 250ml
of distilledwater; an aliquot of 81mlwas further dilutedwith 0.1MHCl
to a final volume of 100 ml. Cibacron Brilliant Red 3B-A (150 mg) was
dissolved in 100 ml of distilled water. The dye solution (5 ml) was fur-
ther diluted to 100 ml with the glycine buffer. Vesicle suspensions
were diluted with distilled water to desirable concentration (1:6, v/v)
before 3 ml of the final dye solution was added. UV–vis absorbance
wasmeasured at 575 nmwith a spectrophotometer (Agilent Technolo-
gies, Santa Clara, CA, USA). The percentage of surface-available chitosan
was calculated using the following equation:
Percentage of surface available chitosan ¼ Cs
Cc
 100
where, Cs is the concentration of chitosan in the sample and Cc is the
concentration of chitosan used to prepare the liposomal formulations.
A chitosan standard solution (0.05 % w/v) was prepared in 0.05 %
(v/v) glacial acetic acid. The standard solution was diluted in glycine
buffer to desired concentrations. The correlation coefficient for the
standard curve was 0.9997 and the minimum detectable amount of
chitosan was 2.27 μg/ml.
2.9. In vitro mucoadhesive properties
The mucoadhesive properties were determined by measuring lipo-
somes binding to the pig mucin (PM) as described earlier (Jøraholmen
et al., 2014). Briefly, non-coated and chitosan-coated liposomes (1 ml)
in original vesicle size weremixedwith equal volume of PM suspension
(400 μg/ml) in 0.05 M phosphate buffer saline and incubated at room
temperature for 2 h, followed by ultracentrifugation (216,000 ×g) for
1 h at 10 °C (Optima LE-80; Beckman Instruments, Palo Alto, CA, USA).
Aliquots of 200 μl (4 from each sample) of the supernatants were trans-
ferred to amicrotitre plate (Costar®UV 96-well plate with UV transpar-
ent flat bottom, Acrylic, Costar®, Corning, NY, USA) and free PM was
measured spectrophotometrically at 251 nm (Microtitre plate reader;
Spectra Max 190 Microplate, Spectrophotometer Molecular devices,
Sunnyvale, CA, USA). The PM binding efficiency was calculated accord-
ing to Naderkhani et al. (2014).
2.10. In vitro RES release
The in vitro RES release experiment was performed by the method
described earlier (Jøraholmen et al., 2014). The Franz cell manual diffu-
sion system (Perme Gear Ink, Diffusion Cells and Systems, Hellertown,
PA, USA) and the heating circulator (Julabo Laboratechnik, F12-ED,
Seelback, Germany) was set to 37 °C. The acceptor chamber (12 ml)
was completely filled with acetate buffer (pH 4.6) containing
CH3COONH4 (77.1 g) and glacial acetic acid (70 ml) and distilled
water up to 1000 ml. Cellophane membrane, cut to appropriate
size, was pre-soaked in the same buffer prior to fixation. Liposomal
samples and controls (RES in propylene glycol) (600 μl) were
added to the donor chambers and the system was properly sealed.
The RES content in all tested samples was determined spectrophoto-
metrically prior to the experiment to assure the same concentration
gradient in the samples and controls, and to assure sink conditions.
Samples (500 μl) were withdrawn from acceptor chamber after 1,
2, 3, 4, 6 and 8 h. The collected samples were replaced by an equal
volume of buffer in the acceptor chamber. All collected samples,
the remaining suspension on and retained in the cellophane mem-
brane were dissolved in methanol and measured spectrophotomet-
rically (Agilent Technologies, Santa Clara, CA, USA) at 306 nm.
2.11. Measurement of SOD activity
The effects of RES and liposomal RES on SOD activity were measured
in LPS-induced J774A.1 cells by the similarmethod as reportedpreviously
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above. The controls for RES and liposomal formulations were medium
containing 0.2% DMSO and empty liposomes, respectively. In both con-
trols, SOD activity inducedwith LPS (1 μg/ml) after 24 h,were expressed
as basal level. The SOD activities (%) exhibited by the LPS-induced mac-
rophages in the presence of test samples (RES, and liposomal RES) at
10 μg/ml were assayed according to the protocol for colorimetric assay
kit. The measurements were performed in triplicates.
2.12. Measurement of NO production
The effects of RES and liposomal RES on production of NO in the LPS-
induced J774A.1 cells were measured as reported previously (Basnet
et al., 2012). The cells were treated with LPS (1 μg/ml) and/or samples
at various concentrations. After 24 h, the effects of the samples (RES,
and liposomal RES) on the production of NO released in the medium
were measured in terms of nitrite formation by Griess reagent (1%
sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, 2.5%
H3PO4) at 550 nm using NaNO2 as the standard. The measurements
were performed in quadruplets. The effects of the RES on the production
of NO were also compared to some well-known anti-oxidants (vitamin
C and vitamin E) and iNOS inhibitor (L-NAME). The controls for RES and
liposomal RES were 0.2% DMSO and empty liposomes, respectively. The
inhibitory activities of RES and liposomal-RES on NO production were
expressed as IC50 (μg/ml).
2.13. Effect on IL-1β and TNF-α production
The effects of RES and liposomal-RES on the production of TNF-α
and IL-1β in the LPS-induced J774A.1 cells were measured as reported
previously (Basnet et al., 2012). The cell medium was replaced with
the medium containing LPS (1 μg/ml) and/or samples (10 μg/ml).
After 24 h, the medium (500 μL) was removed and stored at −70 °C
until cytokine assays were carried out. Controls for RES and liposomal
RES were 0.2% DMSO and empty liposomes, respectively. The produc-
tion of TNF-α or IL-1β in the medium by the LPS-induced cells were
measured and expressed as 100%. Both pro-inflammatory cytokines
(TNF-α and IL-1β) were measured in the same set of experiments by
the assay kits as described in the manufacturer's protocols. Measure-
ments were performed in triplicates.Fig. 1. Chemical structures of resveratrol (trans-3,5,4′-trihydroxystil2.14. Statistical analyses
Data were analyzed using the SPSS 19.0 software (SPSS Inc. Chicago,
IL, USA). Continuous variables are expressed as mean and categorical
variables are reported as percentage. Statistical significance of differ-
ence between the control and test groups or corresponding groups
was determined by one-way ANOVA, and P b 0.05 was considered stat-
ically significant. Results are expressed as mean ± S.D., where n= 3 or
4.
3. Results
3.1. The effect on DPPH/ABTS+• radicals
Although RES, vitamin C and vitamin E are structurally different
(Fig. 1) and differ significantly in their physical properties, they show
similar chemical reaction towards free radicals and anti-oxidative
potentials.
Anti-oxidative activity is expressed as DPPH or ABTS+• radicals scav-
enging capacity of RES. We examined the radical scavenging activity of
RES at 1, 5, 10 and 20 μg/ml concentrations for DPPH or ABTS+• radicals.
The anti-oxidative activities of RES were compared to those of vitamin
C and vitamin E under the similar conditions. All samples showed
concentration-dependent radical scavenging activity and the results
are shown in Fig. 2(A and B).
In a separate experiment, the anti-oxidative activities of RES were
compared with that of vitamin C or vitamin E by measuring their effec-
tive concentrations required for the 50% decrease of radicals (EC50) and
the results are shown in Fig. 3. EC50 for RES were 17.15 and 3.05 μM
against DPPH and ABTS+• radicals, respectively. While vitamin C and vi-
tamin E showed 10.25 and 7.38 μM against DPPH radicals and 7.77 and
6.64 μM against ABTS+• radicals, respectively. Comparing to vitamin C
and vitamin E, RES showed stronger reaction towards ABTS+• radicals
rather than DPPH (Fig. 3).
3.2. Liposomal characteristics
The vesicle sizes, polydispersity index (PI), zeta potential and en-
trapment efficiency of coated and non-coated liposomes are presented
in Table 1. Considering the optimal vesicle size for topical vaginal
administration (Vanic and Skalko-Basnet, 2013) and to assure thebene), vitamin C (ascorbic acid) and vitamin E (α-tocopherol).
Fig. 2. Anti-oxidative activities of resveratrol, vitamin C and vitamin E. A) DPPH radical
scavenging activity B) ABTS + • radical scavenging activity. Results are expressed as per-
centage mean ± SD (n = 3).
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ameter of 200 nm were targeted. The coating resulted in an increase
in the mean liposomal size; the increase in the vesicle size corresponded
to the increasing polymer concentration, as expected. All liposomal
dispersions exhibited lowPI, indicating a rathermonodisperse size distri-
bution. The lowPI confirmed that the extrusion could be a suitablemeth-
od to obtain liposomes of desired vesicle sizewith limited polydispersity.
The differences in zeta potential on liposomal surface between non-
coated and chitosan-coated liposomes also confirmed that liposomes
were indeed coated (Table 1). We also observed the differences be-
tween liposomes coated with 0.1 and 0.3% (w/v) chitosan, respectively.
Moreover, an entrapment efficiency of over 70% of the starting amount
of RES was obtained which is sufficient to assure the required RES con-
centrations for therapeutic effects (Table 1). Although the chitosan-
coating was performed in the presence of unentrapped RES, no signifi-
cant increase in RES incorporation was seen for the chitosan-coatedFig. 3. Anti-oxidative activity of resveratrol, vitamin C and vitamin E expressed as EC50 in
μM. Results are expressed as mean ± SD (n = 3).liposomes. A phospholipid assay was applied to assure that the vesicle
size reduction via extrusion and the chitosan-coating did not result in
a loss of lipids. The loss of lipid was found to be less than 5% and accept-
ed as satisfactory.
3.3. Mucoadhesive properties of liposomal formulation
The increased concentration of polymer is expected to lead to more
efficient coating of liposomes (Li et al., 2009). A colorimetric assay with
the anionic reactive dye (Cibacron Brilliant Red) was performed in the
presence of free chitosan, thus the binding efficiency of chitosan to lipo-
somal surface could not directly be measured. However, for the lower
chitosan concentration (0.1%,w/v), 84% of chitosanwas found to be sur-
face available, whereas 54% of chitosanwas detected on liposomes coat-
ed with higher polymer-concentration (0.3%, w/v). The results are in
agreement with the findings in the literature (Li et al., 2009; Andersen
et al., 2015).
We tested the in vitromucin-binding potential for both coated and
non-coated liposomes to confirm the mucoadhesive properties of
chitosan-coated liposomal delivery system (Fig. 4). Since the vaginal en-
vironment varies in pH, the experiments were performed at pH corre-
sponding to healthy vaginal conditions (4.6) and vaginal bacterial
infections conditions (7.4). The results indicate that PM-bindingproper-
ties are significantly (P b 0.001) improved for chitosan-coated lipo-
somes compared to non-coated liposomes which are in accordance
with the literature (Jøraholmen et al., 2014; Naderkhani et al., 2014).
The superiormucin-binding potential of liposomes coatedwith low chi-
tosan concentration (0.1%, w/v) was confirmed (Jøraholmen et al.,
2014), compared to all other formulations. Importantly, the superiority
was confirmed at both pH, suggesting that mucoadhesiveness will be
assured regardless of the vaginal pH conditions. Non-coated liposomes
are not expected to exhibit mucin-binding activity, however a notice-
able binding efficiency was also observed for non-coated liposomes.
One possible explanation for observed PM-binding to plain liposomes
can be by physical interactions occurring during the ultracentrifugation
and not an actual electrostatic interaction between liposomes and
mucin. However, the binding was significantly lower than PM-binding
of chitosan coated liposomes (0.1 and 0.3%, w/v).
3.4. In vitro release of RES from coated and non-coated liposomes
The Franz diffusion system was employed to assess the RES release
from liposomal formulations comparing the release to free RES in pro-
pylene glycol solution serving as a control. Liposomes coated with the
0.6% of chitosan showed poor mucoadhesive properties (Fig. 4), there-
fore were not included in the RES release study. An apparent sustained
release from all liposomal formulationswas determined (Fig. 5) and the
in vitro release studies confirmed prolonged release of RES from both
the non-coated and chitosan-coated liposomes as compared to the con-
trol. Further, the release of RES was slower from the chitosan-coated li-
posomes as compared to the non-coated liposomes. This indicates that
chitosan-coated liposomes have the ability to prolong the release of
RES to a greater extent than non-coated liposomes.Table 1
Liposomal size, zeta potential and entrapment efficiency of non-coated and chitosan-coat-
ed liposomal resveratrol.
Resveratrol-loaded liposomes
Chitosan (%) Vesicle size (nm) PIa Zeta potential (mv) Entrapment (%)
— 206 ± 10 0.142 −3.17 ± 2.57 80 ± 4
0.1 212 ± 11 0.172 4.15 ± 0.59 77 ± 4
0.3 225 ± 10 0.122 14.77 ± 1.85 74 ± 6
Results are expressed asmean±S.D. (n=3). Data for chitosan solution (0.1 and 0.3 %,w/v)
are presented.
a PI: polydispersity index.
Fig. 4. Pig mucin (PM) binding (%) of non-coated and chitosan-coated liposomes. The
values represent the percentage mean ± SD (n = 3).
Fig. 6. The effects of resveratrol (RES) and liposomal RES on SOD activity in LPS-induced
macrophages. Stock solution of RES in DMSO was diluted with the cell culture medium
euaivalent of RES present in liposomal RES and applied same volume containing 10 μg/
ml as the final concentration to cells. Results are expressed asmean± SD (n=3). Control
for RES and liposomal RES were 0.2% DMSO and empty liposomes, respectively.
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The effects of RES and liposomal RES on SOD activity in LPS-induced
J774A.1 cells were evaluated and results are shown in Fig. 6. Comparing
to the basal SOD activity of the controls, RES increased the SOD activity
by 20%. Under a similar condition, liposomal formulation of RES in-
creased the SOD activity by 26%. Liposomal formulations significantly
increased (P = 0.009) SOD activity as compared to RES solution.3.6. Effect of RES and liposomal RES on NO production
LPS treatment inducesmacrophages to increased amount of NO pro-
duction by the conversion of L-arginine to L-citrulline. Thus produced
unstable NO radical, is rapidly converted to NO2− or NO3−. Therefore
the amount of NO2− measured quantitatively by the Griess reagent can
be directly correlated to the NO production by the macrophages. We
measured theNO2− produced by LPS and RES (1, 5 and 10 μg/ml) treated
cells and expressed the activity as percentage of NO production and re-
sults are shown in Fig. 7. RES showed a concentration-dependent NO
production inhibition. The activities of RES were also compared to that
of vitamin C, vitamin E and L-NAME under similar conditions. Vitamin
C and vitamin E showed only a weak inhibitory activity at higher con-
centrations (10 μg/ml).
L-NAME (iNOS inhibitor) showed, as expected, concentration-
dependent activity at 1, 5, and 10 μg/ml. Under similar conditions, RES
was found to be more potent than L-NAME (Fig. 7). In another similar
experiment, the inhibitory activity of RES and corresponding liposomal
formulations against NO production was measured at 1, 2, 5, 10, 15, 20,
25, and 30 μg/ml RES concentrations. The results were expressed in 50%
inhibitory concentration (IC50) as μg/ml (Fig. 8). RES and corresponding
liposomal formulation showed IC50 as 13.5 and 9.6 μg/ml, respectively.Fig. 5. In vitro resveratrol release from non-coated and chitosan-coated liposomes. *As a
control, resveratrol in the same concentration as in liposomes was dissolved in propylene
glycol. Results are expressed as percentage mean ± SD (n = 3).Liposomal RESwas found to bemore potent than the correspondingRES
solution (P = 0.003), confirming the need for delivery system (Fig. 8).
3.7. Effect of RES and liposomal RES on TNF-α and IL-1β production
We measured the TNF-α and IL-1β production by the LPS-induced
macrophages in the presence of RES or liposomal RES. As compared to
the control group, RES at a concentration of 10 μg/ml inhibited 52% of
TNF-α production. Under the similar condition, liposomal RES inhibited
70% of TNF-α production which were significantly different (P =
0.004). We also measured the effects of RES and liposomal RES on the
production of IL-1β. Compared to the control group, RES and liposomal
RES at a concentration of 10 μg/ml inhibited 60% and 62% of IL-1β
production, respectively (Fig. 9).
4. Discussion
RES acts as a potent defensive anti-oxidant by inhibiting reactive ox-
ygen species (ROS) mainly by activating AMPK (Pangeni et al., 2014). It
exhibits stronger anti-radical activity than α –tocopherol, catechin,
myricetin and naringenin. RES, vitamin C and vitamin E used in our ex-
periments were supplied commercially (99.0% pure). Their structures
are given in Fig. 1. Vitamin C is a hydrophilic and vitamin E a lipophilic
anti-oxidant with well-defined bioavailability. However, RES remains
to be a biopharmaceutical challenge with regard to its solubility limita-
tions (Das et al., 2008). Taken orally RES is relatively well absorbed,
rapidly metabolized and generally well tolerated, although limited
long-term toxicity studies have also been performed (Cottart et al.,
2010). Extensive intestinal and hepatic metabolism is the rate limiting
step for the systemic bioavailability resulting in a half-life of only
8–14 min (Das et al., 2008). With logP N 3.1 it is classified as a class-II
compound in the Biopharmaceutical Classification System. Trans-RES
is a pharmacologically active isomer. RES is a photosensitive compound
and becomes converted into cis-RES after exposure to light for just 1 h in
solution (Singh and Pai, 2014). This is an additional reason to incorpo-
rate RES in liposomal delivery system enabling the protection against
light (Coimbra et al., 2011).
Our interests were in anti-microbial potential of RES, as increasing
number of in vitro and in vivo studies suggest that RES exhibits anti-
parasitic (Trihomonas vaginalis) (Mallo et al., 2013), anti-fungal (Candida
species) (Houille et al., 2014), anti-viral (Docherty et al., 2005) and anti-
bacterial (Nawrocki et al., 2013) activities. Prior to evaluating the anti-
viral potential of liposomal RES, we have focused on the anti-oxidative
and anti-inflammatory activities of RES and corresponding formulation.
Fig. 7. The effects of resveratrol, vitamin C, vitamin E and NAME on NO production in LPS-
induced macrophages. RES: resveratrol; NAME: L-nitro-arginine methyl ester. Results are
expressed as mean ± SD (n = 4).
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tion. The symptoms of inflammation include redness and swelling, which
are caused by increased bloodflow into the tissue. Inflammation is caused
by eicosanoids and cytokines, which are released by injured or infected
cells. There is abundant evidence that certain pro-inflammatory cytokines
such as IL-1β, IL-6, and TNF-α are involved in the process of pathological
infection (Dinarello, 2000). Therefore, to express the anti-inflammatory
activity, we focused on effect of RES on the production of nitric oxide,
IL-1β, and TNF-α.4.1. Liposomal RES
In the past ten years, an increasing number of publications dealing
with RES in nanosystems have been reported (Amri et al., 2012).
Moreover, an extensive list of patents on the use of RES in diverse
formulations indicates increasing interest of academia and indus-
try for its commercialization (Singh and Pai, 2014). The limitation
of the solubility of RES can be overcome by incorporating RES into
delivery system which acts as a solubilizer and improve the delivery of
the drug candidate. Several novel delivery systems were proposed in re-
cent years as means to improve its bioavailability, including polyethylene
glycol-polylactic acid polymeric nanoparticles (Jung et al., 2014), solid
lipid nanoparticles (Teskac andKristl, 2010;Gokce et al., 2012), polymeric
micelles (Lu et al., 2009), RES-loaded poly(N-vinylpyrrolidone)-ƅ-poly(ε-
caprolactone) nanoparticles (Lu et al., 2013). RES self-emulsifying systemFig. 8. The effect of resveratrol (RES) and liposomal RES on NO production in LPS-induced
macrophages. Results are mean ± SD (n=4) showing the amount RES required to show
50% inhibition of NO production (IC50 μg/ml) in J774A.1 cells induced by LPS (1 μg/ml).was shown to increase the uptake by endothelial cells and improve
protection against oxidative stress-mediated death (Amri et al.,
2014). Phospholipids offer means to improve the poor solubility
and consequently low bioavailability of various active compounds
(Fricker et al., 2010). In addition, liposomes improved the chemical
instability of RES by preventing its inactivation through cis–trans isomer-
ization (Coimbra et al., 2011; Scognamiglio et al., 2013). Kristl and co-
workers confirmed that liposome-mediated uptake of RES improved
the cell-stress response in comparison to free RES (Kristl et al., 2009).
The same group (Caddeo et al., 2008) proved the enhanced efficacy of
RES incorporated in liposomes on proliferation and UV-B protection of
cells. Elastic liposomes incorporating RES and quercetin injected subcu-
taneously offered a new strategy for reducing the subcutaneous fat
(Cadena et al., 2013). In spite of improving delivery and solubility of
RES, its wider therapeutic application is still limited because of the
required dose needed to assure therapeutic outcome (Augustin et al.,
2013).
Considering localized vaginal therapy, relatively little is known
about the effect of vesicle size on the delivery of drugs intended for vag-
inal mucosal targeting. However, it was suggested that the nanocarriers
in the size range of 200–500 nm are superior to both much smaller and
also larger nanosystems (das Neves et al., 2011a,2011b). Additionally, it
was reported that the number of liposomes penetrating the mucous
layer increased when the size of the liposomes was reduced to approx-
imately 100 nm for both non- and chitosan-coated liposomes (Takeuchi
et al., 2001). There is usually a correlation between the particle size and
drug entrapment efficiency; small vesicles are expected to offer greater
surface area to interact with the mucus, but bearing less drug load,
whereas larger vesicles enable increased drug loading, nevertheless, re-
duced mucoadhesion due to less surface contact (Vanic and Skalko-
Basnet, 2013).
Liposomes are well-established delivery systems able to incorporate
poorly soluble drugs and enable their aqueous medium-based vaginal
administration (Pavelic et al., 1999; 2005a, 2005b). Liposomes as car-
riers for RES were also studied by several groups targeting various
routes of administration. For example, transferosomes and ethanol-
containing vesicles were used to deliver RES through porcine skin
(Scognamiglio et al., 2013).
Chitosan is oneof themucoadhesive polymers recommended for the
vaginal delivery (Valenta, 2005). Several other potential mucoadhesive
polymers were reported as vaginal delivery systems, such as for exam-
ple Carbopol (Pavelic et al., 2005a,2005b), however the known anti-
microbial activities were the main reason to focus on chitosan in the
present work. Moreover, chitosan is a natural polymer and considered
to be biocompatible, biodegradable and bioadhesive. The cationic prop-
erties of chitosan contribute to itsmucoadhessiveness.When chitosan is
used as a coating material for neutral PC liposomes, it is expected that
hydrogen bonds be created between the phospholipid head groups
and the cationic polysaccharide. In addition to required mucoadhesive
properties, chitosan-coating of liposomes may present improved con-
trolled drug delivery and stabilization of liposomes (Jøraholmen et al.,
2014). Moreover, chitosan also exhibits anti-microbial activity against
vaginal pathogens (Kim et al., 2003) and its ability to disrupt vaginal
bacterial biofilms makes chitosan superior polymer in localized vaginal
therapy (Kandimalla et al., 2013). Interactions between the cationic
chitosan and the negatively charged mucosal surface are shown to ren-
der excellentmucoadhesive properties,making this polymer awell suit-
ed coating material for drug delivery systems intended for mucosal
tissues (Meng et al., 2011). Our results are in agreementwith thefindings
ofMeng et al.who reported that chitosan-coated nanoparticles in sizes of
about 200 and 300 nm exhibited significantly enhanced mucoadhesive
properties on porcine tissue (Meng et al., 2011).
The only other report, to the best of our knowledge, on chitosan-
coated liposomes containing RES is by Park et al. who tested potential
of this system to provide transdermal delivery of RES as delaying skin-
aging substance (Park et al., 2014). They also observed that liposomes
Fig. 9. The effects of resveratrol (RES) and liposomal RES on IL-1β and TNF-α production in LPS-induced macrophages. Results are expressed as percentage mean ± SD (n = 3).
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tegrity better than those coated with higher concentrations of polymer
(Park et al., 2014).
During the process of chitosan-coating of liposomes, the amount of
polymer interacting with the liposomes is expected to increase with an
increase in the starting concentration of chitosan (Li et al., 2009). Our
findings that lower chitosan concentrations result in more surface-
available chitosan are in agreement with Guo et al. who reported that
chitosan-coating of liposomes reached a saturation state when exceeded
0.1% concentration (Guo et al., 2003).
The effectiveness of drug delivery at themucosal site is dependent on
a series of interconnected actions including i) distribution and retention
of nanosystems on the mucosal surface, ii) their penetration into/
through the mucus mesh, and iii) release profile of the drug (Vanic and
Skalko-Basnet, 2013). The RES release (Fig. 5) indicates that chitosan-
coated liposomes enabled sustained release. Chitosan-coated liposomes
were superior to non-coated liposomes regarding the ability to sustained
RES release, confirming our aim that chitosan-coating assures not only
the mucoadhesivness but also the prolonged RES release. This is of
great importance considering the vaginal administration, as reduced
frequency in need for repeated administration correlates with better pa-
tient compliance.
4.2. Anti-oxidative activity
Invading pathogens create oxidative stress because of over produc-
tion of ROS during increased metabolic activities and immune cell reac-
tion. A number of cellular processes including aerobic metabolism can
easily supply one electron to cytoplasmic oxygen to generate O2•−
which is also an essential step for the cellular communication and
signaling (Afanas'ev, 2007). Normally when the concentration of O2•− in-
creases the activity of superoxide dismutase (SOD) and catalase (CAT)
increase to dismutate the toxic amount of O2•− to non-toxic molecules
such as water and oxygen. However, as the production of O2•− and
dismutation process are not balanced, there will be the over production
of O2•− or H2O2 which can either easily be transformed into the ONOO−
by reacting with NO•, the OH• by Fenton reaction (catalyzed by Fe+++/
Fe++) or the R• by increased peroxidase activity. The free radicals-ROS,
especially ONOO−, OH•, and R• are very powerful oxidants as compared
to O2•− and H2O2. The pathogen-induced ROS and/or free radicals gener-
ated in vivo together with the pro-inflammatory cytokines can cause
significant damage to cells hasten the inflammation and infection. The
anti-oxidants can attenuate the direct effect of radicals by deleting or
scavenging which may inhibit the inflammatory processes.
RES was exhibited strong reaction to free radicals comparable with
those of vitamin C and vitamin E. In addition, its effects on enhancing
the SOD activity would make it a stronger candidate as an anti-
oxidant. RES showed stronger radical scavenging activity for ABTS+•
radicals, comparing to DPPH free radicals (Figs. 2 and 3). The superior
activity of RES (EC50 of 3.05 μM) compared to the other anti-oxidantsin case of ABTS+• radicals, is in agreement with literature (Stojanovic
et al., 2001). The reaction with ABTS+• radicals involves an electron
transfer process while H-atom transfer mechanism involves in DPPH
radical reaction therefore, ABTS+• radicals are more reactive with the
RES type polyphenols (Gülçin, 2010). Vanaja and colleagues re-
ported on the enhanced anti-oxidative activities of liposomal RES
as compared to free RES based on the inhibition of 2,2′-azobis(2-
amidinopropane)dihydrochloride (AAPH)-induced luminol enhanced
chemiluminescence assay (Vanaja et al., 2013). Only one report found
so far describes DPPH radical assay directly used for liposomal suspen-
sions measuring with the UV–vis spectrophotometer (Caddeo et al.,
2013). It might be possible that the alcoholic solution of DPPH radical
solubilizes the liposomal suspension by the destructing of liposomal
vesicles to release free RES. We do not see any advantage of measuring
direct radical scavenging activity for anti-oxidants-associated liposomal
suspension unless used lipid is itself anti-oxidants. RES also showed
pro-oxidant properties at higher concentration like other common
anti-oxidants since it is a redox-chemistry and clinical application
depends on the drug concentration (de la Lastra and Villegas, 2007).
RES is reported to exhibit anti-oxidative effect directly either by
donating an electron to free radicals and/or providing hydrogen or indi-
rectly by enhancing the SOD activity (Gülçin, 2010; Zheng et al., 2010).
We also compared the in vitro SOD activities of RES and the correspond-
ing liposomal formulation. RES and corresponding liposomal delivery
system significantly enhanced the in vitro SOD activities comparing to
controls. Moreover, liposomal RES, under similar conditions, was found
superior to RES (Fig. 6).
4.3. Anti-inflammatory activity
Vaginal inflammation and infection are very common and every
woman experiences them at least once in her life. They can be
caused by various pathogens such as virus, bacteria, fungi, or para-
site (Trichimonas). Contamination of such pathogens initiates in-
flammation and their rapid growth lead to infection. Inflammation
is the root cause of severe metabolic dysfunction including loss of
cell integrity, enzyme function, genomic stability etc. (Hanahan
andWeinberg, 2000). Nitric oxide is known not only as a free radical
and vasodilator; it also plays a very important role in the pathways of
inflammation and as an immunomodulator (Coleman, 2001). Some
free radicals mainly such as O2•−, OH•, and NO• radicals along with
non-free radical species such as H2O2 and HNO2 are responsible for me-
diating the inflammation (Khan et al., 2008). In addition, cytokines such
as TNF-α and IL-1β are playing important roles in chronic inflammation
processes and persistent inflammatory tissue damage leading to each
stage of infection. Moreover, pro-inflammatory molecules such as NF-
κB and non-steroidal anti-inflammatory gene-1 dominating over the
effect of SOD, CAT and glutathione peroxidase (GPX), together with a
non-enzymatic system such as glutathione and vitamins (A, C, and
E) constitute the defense to overreaction of free radicals (Finkel and
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bition of NF-κB activity via multiple mechanisms (Surh and Na, 2008).
RES inhibited HSV replication by suppressing NF-κB activity (Faith
et al., 2006). NF-κB is a host nuclear transcription factor, activated by
multiple stimuli, including inflammatory cytokines, growth factors and
bacterial or viral infections (Santoro et al., 2003). RES also showed anti-
inflammatory activity by interfering both transcription (Subbaramaiah
et al., 1998) and catalytic (Jang et al., 1997) activities of the COX2enzyme.
Therefore, the anti-inflammatory activities of RES can be suggested
through ostensibly independent effects on NF-κB, cyclooxygenase and
IL-1β (Baur and Sinclair, 2006).
In our experiments, RESwas found to bemore potent than vitamin C
or vitamin E in scavenging ABTS•+ radicals (Fig. 3). RES was also found
to be a stronger inhibitor of NO production as compared to iNOS inhib-
itor L-NAME, which strengthens its potential as an anti-inflammatory
agent (Fig. 7). In addition, liposomal RES showed superior inhibitory
properties onNOproduction (Fig. 8). RES significantly inhibited thepro-
duction of cytokines TNF-α and IL-1β in the LPS-activatedmacrophages.
In all those set of experiments, liposomal RES was found to be more
potent as compared with the corresponding RES especially for TNF-α
(Fig. 9). The increased inhibitory activity of liposomal RES might be
the consequence of enhanced cellular uptake and/or maximized effect
of RES. It requires further investigation at cellular and sub-cellular
levels. If the finding reported here can be directly correlated to the nor-
mal epithelial cells in human, liposomal formulation of RES for topical
anti-inflammatory treatment would be an optimal formulation.
Moreover, trichomoniasis is the most common non-viral STD in the
worlds. Currently, metronidazole (MDZ) and other 5-nitroimidazoles
(tinidazole, ornidazole, and secnidazole), thepotent drugs against infec-
tions caused by anaerobic or microaerophilic microorganisms, are the
only recommended drugs for standard treatment of T. vaginalis infec-
tion. However, resistance of T. vaginalis to MDZ, allergic reactions, and
failure to remedy the infection with two consecutive courses of treat-
ment have been reported (Cudmore et al., 2004; Das et al., 2005; Harp
and Chowdhury, 2011; Muzny et al., 2012). Studies have shown that
at least 5% of clinical cases of trichomoniasis are caused by parasites
that are resistant to the above-mentioned drugs. Because of the lack of
approved alternative treatments, the only option for patientswith resis-
tant infections is to use higher and sometimes toxic doses of MDZ,
which leads to an increase in the occurrence of side effects (Cudmore
et al., 2004). On the other hand, RES showed in vitro anti-parasitic effect
against T. vaginalis by altering hydrogenosomal dysfunction (Mallo
et al., 2013). Therefore, regarding to the potent anti-oxidative and
anti-inflammatory activities and multi-targeted mechanisms, RES could
be a potential therapeutic candidate especially for pregnant women
against common inflammations and infections caused by diverse type
pathogens. Although we have not tested the newly developed systems
against T. vaginalis or particular pathogens, it is to be expected that the
developed system can assure the necessary concentration of RES at
vaginal site enabling sufficient interaction time and consequent anti-
microbial action.5. Conclusions
Our findings further confirmed RES as a strong anti-oxidant as well
as anti-inflammatory compound. The liposomal formulation solubilized
RES and enhanced its anti-oxidative and anti-inflammatory properties.
With a combination of liposomal carrier as a solubilizer for RES and
the mucoadhesive properties of chitosan in chitosan-coated liposomes,
development of an optimal vaginal drug delivery system with specific,
prolonged and controlled drug release properties might be possible to
enable a controlled delivery as well as provide chemical stability for
RES. Moreover, anti-microbial properties of chitosan will provide addi-
tional advantage against vaginal pathogens. However, further in vivo
and clinical studies are needed to obtain the direct evidences.Conflict of interest
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Abstract 
In recent years, a great deal of attention has been given to the surface modification of liposomes as means 
to prolong the residence time in body or body cavities. In respect to mucosal sites, it has been agreed that 
mucoadhesive polymers prolong the residence time. Recent findings, however, indicated that nanocarrier 
systems based on the surface-available polyethylene glycol (PEG) and able to penetrate mucus, assure 
closer contact with the epithelium, and improved drug delivery to vaginal mucosa. To elaborate on the 
proposed hypothesis, we developed the mucus-penetrating, PEGylated liposomes, containing Interferon 
alpha-2b (IFN α-2b) destined to provide localized therapy in the vaginal tissue. IFN α-2b was chosen as a 
relevant biological with potential to treat human papilloma virus (HPV) infections of vagina. The PEGylated 
vesicles had a size of 181 ± 8 nm, a negative zeta potential of – 13 mV and an entrapment efficiency of 81 
± 10 %. In vitro release experiments on model membrane showed a nearly non-existent IFN α-2b release 
from both the control and liposomally-associated IFN α-2b. However, the ex vivo penetration studies 
performed on vaginal tissue from pregnant sheep, showed a clear elevated IFN α-2b penetration from 
PEGylated liposomes compared to the control. Furthermore, mucin studies confirmed the absence of 
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interaction between the PEG modified liposomes and mucin indicating that the liposomes have the ability 
to penetrate mucus and reach the deeper epithelium. The system seems to have a promise in topical 
delivery of IFN α-2b and provide enhanced efficacy in local anti-viral therapy. 
Key words: PEGylated liposomes, IFN α-2b, vaginal therapy, HPV, mucus-penetrating 
 
1. Introduction 
It is estimated that 80 % of all sexually active women will acquire vaginal human papilloma virus (HPV) 
infection by the age of 50 (Viera et al., 2010). Genital papilloma virus is transmitted via mucosal surfaces 
and is responsible for genital warts. Current therapy fails to eradicate warts and eliminate the virus and 
the recurrence rate is up to 90 % (Stockfleth and Meyer, 2012). For visible lesions, intralesional interferon 
alpha-2b (IFN α-2b) appears to be applicable treatment; however, this treatment option involves pain and 
severe side effects due to systemic exposure. Moreover, this is not suitable treatment for latent or 
subclinical infections and a sophisticated non-invasive approach is desirable. The potential of topical 
treatment of genital warts was one of the first studies reporting vaginal applications of liposomal drugs. In 
preliminary clinical testing, topical treatment with liposomal IFN α-2b achieved complete resolution of 
cervical lesions in female patient at the end of therapy (Foldvari and Moreland, 1997). Liposomal 
formulations can provide a prolonged half-life of IFN α-2b and a shift of distribution towards infected 
tissues due to increased capillary permeability, thereby improving efficacy and reducing toxicity (Wang et 
al., 2002). Additionally, incorporating IFN α-2b in liposomal formulations may increase its stability and alter 
its pharmacokinetics, two issues which often limit the success of IFN therapy (Karau et al., 1996; Yang et 
al., 2006). 
To achieve a successful local delivery to mucosal tissue, the penetration into/through the mucus mesh, 
uniform distribution of drug into the underlying tissue and maintained sufficiently high drug concentration 
are required. Vaginal mucosal surface is protected by mucus, a physical barrier in the form of an adhesive 
gel that stick to most particles, preventing all foreign particles to penetrate to the epithelium surface. 
Nevertheless, viruses have the ability to overcome this barrier and cause mucosal infection (Ensign et al., 
2012). For drug delivery systems to be able to successfully reach mucosal tissue, biomimicking of the virus 
properties might be a promising approach. 
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Polyethylene glycol (PEG) is an uncharged hydrophilic polymer widely applied in pharmaceutical 
formulations, including those for topical vaginal therapy. When used as a coating material, PEG enables 
nanoparticles to diffuse through vaginal mucus by eliminating the adhesive interactions between the 
nanoparticles and mucus (Ensign et al., 2012; Lai et al., 2007), achieving a closer contact to the vaginal 
epithelium, and improved drug effectiveness is possible. With the combination of the carrier properties of 
liposomes as a protective carrier for sensitive biologicals and the mucoresistant properties of PEG available 
on liposomal surface, development of an optimal vaginal drug delivery system with controlled drug release 
in close proximity to the vaginal epithelium is possible. 
Following this hypothesis, we developed liposomal carriers containing IFN α-2b with surface-available low 
molecular weight PEG (Mw of 2000), aiming to obtain a mucus-penetrating delivery system able to 
distribute IFN α-2b to vaginal mucosa enabling improved localized therapy. 
 
 
2. Materials and Methods 
2.1. Materials 
Lipoid S 100 (PC, soybean lecithin, > 94 % phosphatidylcholine) was a generous gift from Lipoid GmbH, 
Ludwigshafen, Germany; methoxy poly (ethylene glycol)-modified lipids (mPEG 2000) was from the same 
manufacturer. IntronA® 50 million IU/mL injection fluid in multiple dose pen was the product of MSD AS, 
Drammen, Norway. Acetic acid, bovine serum albumin, calcium hydroxide, cholesterol, fructose, glycerol, 
mucin from porcine stomach (type III, bound sialic acid 0.5 % - 1.5 %, partially purified), potassium 
phosphate monobasic, Sephadex® G-50, Triton® X-100 and zinc chloride were all purchased from Sigma-
Aldrich Chemie GMbH, Steinheim, Germany. Di-sodium hydrogen phosphate, sodium dihydrogen 
phosphate monohydrate, potassium chloride and titriplex (ethylenedinitrilotetraacetic acid disodium salt 
dihydrate) were obtained from Merck KGaA, Darmstadt, Germany. Glucose, lactic acid, polysorbatum, 
potassium hydroxide, sodium citrate dihydrate and urea were the products of NMD, Oslo, Norway. 
Ammonium acetate, magnesium chloride and potassium chloride was the product of VWR International 





2.2. Preparation of liposomes 
Liposomes were prepared by the film hydration method as described earlier (Jøraholmen et al., 2014). 
Briefly, cholesterol (10 mg), mPEG 2000 (36.3 mg) and PC (200 mg) were dissolved in methanol and 
chloroform (1:1, v/v) in a round bottom flask. Solvents were removed through evaporation (Büchi 
rotavapor R-124 with vacuum controller B-721, Büchi Vac® V-500, Büchi Labortechnik, Flawil, Switzerland) 
for 2 hours at 50 mm Hg and 50 °C. The remaining film was flushed with nitrogen to assure no residual 
solvents. The lipid film was then re-suspended in 5 mL of IFN α-2b solution (2 mIU/mL) from IntronA® 50 
million IU/mL injection fluid and Intron A buffer (pH 7.4, 7.5 g/L NaCl, 1.8 g/L NaH2PO4, 1.3 g/L Na2HPO4, 
0.1 g/L EDTA and 0.1 g/L Polysorbate 80). Empty liposomes were prepared in a similar way, merely the film 
was re-suspended in Intron A buffer. Liposomal suspensions were stored in refrigerator (4 - 8˚C) for at 
least 12 hours prior to further use. 
 
2.3. Vesicle size reduction 
Liposomal size was reduced by the extrusion through polycarbonate membranes (Nuclepore Track-Etch 
Membran, Whatman House, Maidstone, UK) (Jøraholmen et al., 2015). The extrusion was performed 
stepwise through 0.8, 0.4 and 0.2 µm pore size filters (for each step, 3 extrusions were executed). Extruded 
liposomes were stored in refrigerator for at least 6 hours prior to further use. 
 
2.4. Particle size analysis 
The particle size distribution of liposomal samples was determined by photon correlation spectroscopy 
(Submicron particle sizer model 370, Nicomp, Santa Barbara, California, USA). To avoid interference by 
dust particles, test tubes used for the determination were filled with distilled water and sonicated for 10 
min in ultrasonic bath, then rinsed with filtered, distilled water (using 0.2 µm filter) prior to the 
measurements. Small aliquots of the samples were diluted with the filtered, distilled water to obtain a 
particle intensity of approximately 200-350 kHz (Jøraholmen et al., 2014). All samples preparations were 
performed in a laminar airflow bench. Particle size analyses were run in vesicle mode and intensity 





2.5. Zeta potential measurements 
Zeta potential measurements were performed on a Malvern Zetasizer Nano ZS (Malvern, Oxford, UK). Prior 
to measurement, the measurement cells were properly cleaned with ethanol and filtrated water, 
respectively. The liposomal suspensions were diluted in filtrated water to appropriate concentrations 
(typically 1:20) before loading the sample into the cells (Jøraholmen et al., 2015). Three parallels were 
determined for each sample measurement. 
 
2.6. IFN α-2b entrapment 
Liposomally entrapped IFN α-2b and free drug were separated by size-exclusion gel chromatography. 
Sephadex® G-50 in Intron A buffer (75 mg/mL) was left to swell overnight (at 4-8 °C). The gel was packed 
in a column (50 mL) and flushed with Intron A buffer. The stationary phase measured 65 cm3. Liposomal 
sample containing IFN α-2b (1.2 mL) was applied on top of the column and 100 fractions of 1 mL was 
collected. Eluate time was 1.8 mL/min. The column was properly rinsed with Intron A buffer (150 ml) 
before and after each sample. 
An enzyme-linked immunoassay kit (VeriKine™ Human IFN α-2b Multi-Subtype ELISA kit) was used for the 
quantification of IFN α-2b. Aliquots of the samples were diluted in 0.1 % Triton (Triton X-100 in Intron A 
buffer) to disintegrate liposomes and further diluted to suitable concentrations with Intron A buffer. The 
procedure was performed according to enclosed instructions in the ELISA kit. In brief, standards and 
diluted samples were added to microplate coated with IFN α-2b antibodies. Diluted antibody solution, 
diluted horseradish peroxidase (HPR) and tetramethyl-benzidine (TMB) substrate were added 
step-wise after 1 hour incubation. Finally, the reaction-terminating solution was added after 15 min 
incubation. Amount of liposomally-associated IFN α-2b was determined by UV spectrophotometry at 450 
nm (Microtitre plate reader; Spectra Max 190 Microplate, Spectrophotometer Molecular devices, 





2.7. In vitro release 
Vaginal fluid simulant (3.51 g/L NaCl, 1.40 g/L KOH, 0.222 g/L Ca(OH)2, 0.018 g/L bovine serum albumin, 2 
g/L lactic acid, 1 g/L acetic acid, 0.16 g/L glycerol, 0.4 g/L urea, 5 g/L glucose) was prepared according to 
Owen and Katz (1999). Measured pH was 4.6. 
The in vitro IFN α-2b release experiment was performed on the Franz cell manual diffusion system (Perme 
Gear Ink, Diffusion cells and Systems, Hellertown, USA) as described earlier (Jøraholmen et al., 2014). The 
system and accessories were properly cleaned with methanol, demineralized water and distilled water, 
respectively, prior to experiment. The heating circulator (Julabo Laboratechnik, F12-ED, Seelback, 
Germany) was set to 37 °C. The acceptor chambers (12.1 mL) were completely filled with acetate buffer 
(pH 4.6; 77.1 g CH3COONH4, 70 mL glacial acetic acid and distilled water up to 1000 mL). Polyamide 
membrane (Sartorius polyamide membrane, 0.2 μm pore size, Sartorius AG, Gröttingen, Germany) was 
cut to appropriate size (diffusion area of 1.77 cm2) and fixed between donor and acceptor chambers. The 
IFN α-2b content in all tested samples was determined (ELISA) prior to the experiment to prepare a control 
solution (IFN α-2b in Intron A buffer) containing similar drug concentration. Liposomal samples and 
controls (each in volume of 550 µL) as well as vaginal fluid simulant (50 µL) were added in the donor 
chambers and the system was properly sealed. Sampling from acceptor chamber (500 µL) was done after 
1, 2, 4, 6 and 8 hours and all the samples withdrawn from the acceptor chamber were replaced by an equal 
volume of acetate buffer. Concentrations of IFN α-2b in the withdrawn samples, remaining in donor 
chamber and retained in the polyamide membrane were determined with ELISA kit and UV 
spectrophotometry as described above. The experiments were performed in triplicates. 
 
2.8. Preparation of tissue 
Vaginal tissue from the pregnant sheep was obtained from the Laboratory Animal Centre, University of 
Oulu, Finland. The experiments were performed according to the guidelines of the National Animal 
Experiment Board in Finland. The vaginal tissue was carefully removed from the underlying tissue, cleaned 
and moisten with physiological solution (pH 7.4), packed in clinging film, and then frozen (-20 °C). Prior to 
the experiments, the tissue was left to defrost in phosphate buffer (pH 7.4) at room temperature for at 




2.9. Ex vivo penetration 
The experiment was performed on the Franz cell manual diffusion system like described above. Briefly, 
the acceptor chamber was filled up with phosphate buffer (pH 7.4, 8 g/L NaCl, 0.19 g/L KH2PO4, and 2.38 
g/L Na2HPO4). Sheep vaginal tissue was defrosted, cut to appropriate size (1.77 cm2) and fixed between 
donor and acceptor chamber. Samples and controls (550 µL), with similar amount of IFN α-2b, as well as 
vaginal fluid simulant (50 µL) were added in the donor chambers and the system was properly sealed. 
Aliquots (500 µL) were collected after 1, 2, 4, 6 and 8 hours and replaced by an equal volume of phosphate 
buffer. Amount of IFN α-2b in the collected samples, remaining in donor chamber and retained in the 
vaginal tissue were determined with ElISA kit and UV spectrophotometry as described above. The 
experiments were performed in triplicates. 
 
2.10. In vitro mucin-binding 
The binding of PEGylated liposomes to pig mucin (PM) was determined to confirm the lack of 
mucoadhesiveness. The test was performed as described earlier (Jøraholmen et al., 2015). Briefly, empty 
liposomes (1 mL) with original vesicle size was added to an equal volume of PM suspension (400 μg/mL) 
in phosphate buffer (pH 7.4) and acetate buffer (pH 4.6), respectively. Incubation at room temperature for 
2 hours was followed by ultracentrifugation at 216 000 g for 1 hour, at 10 °C (Optima LE-80; Beckman 
Instruments, Palo Alto, California, USA). From the supernatant, 4 aliquots of 200 µL were transferred to a 
microtitre plate (Costar® UV 96-well plate with UV transparent flat bottom, Acrylic, Costar®, Corning, New 
York, USA) and free PM was measured spectroscopically at 251 nm (Microtitre plate reader; Spectra Max 
190 Microplate, Spectrophotometer Molecular devices, Sunnyvale, California, USA). PM binding efficiency 
was calculated according to Naderkhani et al. (2014). The experiments were performed in triplicates. 
 
2.11. Stability of PEGylated liposomes in the presence of biological fluids 
Human semen simulant was prepared according to Owen and Katz (2005). Briefly, solution 2 (101 mg CaCl2 
· 2H2O, 15.13 mL H2O), the solution 3 (92 mg MgCl2 · 6H2O, 15.13 mL) and further solution 4 (34.4 mg ZnCl2, 
15.13 mL H2O) were added to solution 1 (5.6 mL 0.123 M NaH2PO4 · H2O, 49.14 mL 0.123 M Na2HPO4, 813 
mg sodium citrate dehydrate, 90.8 mg KCl, 88.1 mg KOH, 272 mg fructose, 102 mg glucose anhydrase, 62 
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mg lactic acid, 45 mg urea, 5.04 mg bovine serum albumin). The solutions were mixed and pH was adjusted 
to 7.7 with sodium hydroxide. 
Aliquots (500 µL) of liposomal suspensions containing IFN α-2b (free of unentrapped IFN) were added to 
human semen simulant (500 µL) and vaginal fluid simulant (50 µL), and incubated at room temperature 
for 2 hours. Potentially leaked (free) IFN α-2b was separated from liposomally-associated IFN α-2b by size-
exclusion gel chromatography (according to the method described earlier). Quantification of IFN α-2b in 
fractions was done with ELISA kit and UV spectrophotometry as described above. 
 
2.12. Statistical analyses 
For comparison of two means, statistical significance was determined by the student's t-test. A significance 
level of p < 0.05 was considered to be acceptable. 
 
3. Results and Discussion 
3.1. Liposomal characteristics 
The effectiveness of local drug delivery at the vaginal site is determined by the physicochemical 
characteristics of the delivery system. The vesicle size affects the ability to fit within the mucin pores, while 
the particles surface charge and properties establish if there will be attraction or repulsion to mucus. Thus, 
the main focus in the development of a system aiming for local therapy at the mucosal site is controlling 
the surface properties, particle size and surface charge (Vanić and Škalko-Basnet, 2013). Penetration into 
mucus allows closer contact with the vaginal epithelium and enables improved drug effectiveness. The 
protective barrier function of mucus against all foreign particles complicates this approach, however, virus 
have the ability to penetrate mucus and cause mucosal infection. Development of delivery systems that 
are capable of imitating this property is an interesting strategy in the treatment of the same infections. 
Polyethylene glycol (PEG) available on vesicle surface is shown to effectively minimize the adhesive 
interactions between vesicles and mucus, creating mucus-penetrating particles that can efficiently 
penetrate the human mucus (Tang et al., 2009; Lai et al., 2007). The surface density and molecular weight 
of PEG affect the particle transport, and literature indicates that dense coating with low molecular weight 
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PEG increases the transport rate through mucus (Lai et al., 2009a). By modifying liposomal surface with 
low molecular weight PEG we aimed to develop an advanced carrier for IFN α-2b for the local therapy at 
mucosal site. 
Although there is no consensus regarding the effect of vesicle size on mucosal targeting at vaginal site, it 
is known that small particles will easily be trapped in the mucus mesh while larger particles will be retained 
on the mucus surface. Lai et al. (2009a) showed that larger particles (200-500 nm) densely coated with 
PEG are more rapidly transported through fresh undiluted human mucus, than the corresponding particles 
of smaller size (100 nm). Viruses with diameters between 30 and 200 nm are able to reach and infect the 
vaginal mucosa successfully (Wong et al., 2014). Therefore, we aimed for a vesicle size of 200 nm. The 
vesicle size of our PEGylated liposomes was close to the targeted size range (Table 1). We reported earlier 
(Jøraholmen et al., 2015) that the extrusion as a size reduction method can be applied to obtain vesicle 
size in desired size range with favourable polydispersity. Our liposomes exhibited rather monodisperse 
size distribution (Table 1). 
Table 1: Characteristics of PEGylated liposomes containing IFN α-2b (n = 3). 
 Vesicle size (nm) PI* Zeta potential (mV) Entrapment (%) 
PEGylated liposomes 
containing IFN α-2b 
181 ± 8 0.129 - 13.33 ± 0.81 81 ± 10 
*Polydispersity index 
Considering optimal mucus-penetration, a nearly neutral surface charge is desirable to assure 
mucoresistant properties (Lai et al., 2009a). However, it is also known that a negatively charged 
component present in the liposomal bilayer is beneficial for a stable association and will improve IFN α-2b 
entrapment and prevent drug leakage from the liposomes (Karau et al., 1996). Our PEGylated liposomes 
had a slightly negative zeta potential (Table 1). However, as seen in mucoadhesiveness testing, the charge 
did not contribute to mucoadhesiveness. 
Even if the system exhibits desired mucoresistant properties, it is very important that the drug load is 
sufficient to achieve desired therapeutic response. We were able to achieve rather high entrapment 
efficiency of 81 % (Table 1). This is in accordance with literature data (Yang et al., 2006; Vyas et al., 2006; 
Takeuchi et al., 1999; Li et al. 2011;). By incorporating IFN α-2b in liposomal formulations, an increase in 
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IFN α-2b stability and positive alteration of the pharmacokinetics can be obtained (Karau et al., 1996; Yang 
et al., 2006). 
 
3.2. Mucoresistant properties 
A great deal of older literature suggested that PEG owns mucoadhesive properties that are expressed by 
the interpenetration effects between PEG chains and mucus (Huang et al., 2000; Serra et al., 2006; 
Yoncheva et al., 2005). Very recent studies, however, have demonstrated that PEG-modified nanoparticles 
minimize mucoadhesion and effectively penetrate the mucus enabling closer contact to the underlying 
epithelium (Tang et al., 2009; Lai et al., 2007; Ensign et al., 2012). It is suggested that the molecular weight 
of PEG is the determining factor whether PEG will exhibit mucoadhesive or mucoresistant characteristics 
and recent findings indicate that when densely coated with low molecular weight PEG, nanoparticles avoid 
adhesive interactions with mucus (Ensign et al., 2012; Lai et al., 2007; Wong et al., 2014). 
To confirm that PEG on liposomal surface has a mucoresistant effect and contributes to a reduced 
association between liposomes and mucus, the binding between mucin and liposomal preparations was 
determined. Commercial pig mucin (PM) is commonly used as a mucus substitute due to similarity in the 
structure and molecular weight of PM and human mucus (Groo and Lagarce, 2014). Based on the facts 
that the vaginal pH varies in healthy and infected, as well as pre- and post-menopausal women, the 
experiment was performed at conditions of both a healthy vaginal environment (pH 4.6) and at conditions 
expected to occur during the vaginal bacterial infection and post menopause (pH 7.4). As expected, the 
PEGylated liposomes did not exhibit mucin-binding activity (Figure 1). The results indicate a significantly 
reduced binding efficiency within the different pH conditions for the PEGylated liposomes compared to 




Figure 1: Mucin-binding of PEGylated, non-coated and chitosan-coated liposomes. Results are expressed 
as percentage mean ± SD (n = 3). 
The modest mucin-binding observed for the PEGylated liposomes is likely to be the result of physical 
interactions due to ultracentrifugation and not the electrostatic interactions. Liposomes coated with the 
low chitosan concentration (0.1 %, w/v) exhibited a superior interaction with mucin compared to non-
coated liposomes (Jøraholmen et al., 2015). 
The absence of mucin-binding activity coincide with the expectation of mucoresistant properties of PEG-
modified liposomes. The results indicate that the PEGylated liposomes might be able to penetrate the 
mucus and assure closer contact with the epithelium, thus, enhance mucosal delivery of incorporated drug 
and improve its localized therapeutic outcome. However, one has to consider that the retention time at 
vaginal site might be insufficient to assure that an adequate amount can actually penetrate mucus due to 
lack of mucoadhesion and rapid clearance by vaginal discharge. To confirm that mucoresistant delivery 
system has sufficient time to stay in a closer contact with the vaginal epithelium and assure penetration 
in deeper layers, in vivo testing in infected animals would be required. 
Mucin fibres in the healthy human vaginal mucus are negatively charged and found to have a diameter of 
approximately 340 nm (Lai et al., 2007). Mucus properties are affected by the environmental changes, 
such as changes in pH due to vaginal infections and the viscosity of vaginal fluid. When exposed to bacterial 
vaginosis, a reduction in the viscosity of vaginal fluid causes reduced barrier properties and increased risk 
of infection (Lai et al., 2009b). It is further suggested that mucoadhesive nanoparticles may disrupt the 
protective microstructure of mucus by increasing the average pore size of mucin fibers. This can provide 
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easier access for foreign particles to vaginal mucosa, including the pathogens and other potentially toxic 
nanomaterials, due to the impaired mucus barrier. This phenomena needs to be further evaluated in in 
vivo testing. However, the limited literature data indicate that the mucoresistant particles did not exhibit 
similar effect on the cervicovaginal mucus (Wang et al., 2011). 
 
3.3. In vitro IFN α-2b release 
When evaluating in vitro drug release from topical formulations, including those intended for vaginal use, 
the Franz cell diffusion system is generally considered one of the most appropriate methods (Brown et al., 
2011). In addition to the ability to incorporate both lipophilic and hydrophilic substances, liposomes can 
provide controlled release of incorporated drug (Jøraholmen et al., 2014), and we followed the release of 
liposomally-associated IFN α-2b over 8 hours compared to the IFN α-2b release from a control solution. 
The experimental setup was designed mimicking the human conditions; the acceptor medium had the pH 
of healthy human vaginal environment (4.6) and a temperature of 37 °C. Further, the experiment was 
performed in the presence of simulated vaginal fluid, since it is known that the flow, retention, drug 
delivery kinetics, and bioactivity of vaginal formulations are influenced by the compounds from the vaginal 
fluid (Owen and Katz, 1999). Use of the vaginal fluid simulant has been proven to assist in in vitro 
evaluations of contraceptive and prophylactic drug delivery systems (Sassi et al., 2008). 
 
Figure 2: In vitro IFN α-2b release. Results are expressed as percentage mean ± SD (n = 3). 
























Initially, both PEGylated liposomes and control solution showed a strongly retained in vitro release of IFN 
α-2b (Figure 2). Even though the release of liposomally-associated IFN α-2b increased significantly (p < 
0.001) compared to the control solution after 8 hours, the release was very limited. A considerable amount 
of IFN α-2b from the control solution was retained within the artificial membrane (Figure 3). Although the 
pore size of the membrane should be sufficient to allow the passage of IFN molecules through, it seems 
that IFN α-2b was mostly retained in the membrane, or stayed in the liposomes on the membrane surface 
(Figure 3). 
 
Figure 3: IFN α-2b distribution after 8 hours of in vitro release. 
*IFN α-2b in Intron A buffer. 
 
3.4. Ex vivo penetration 
Franz cell diffusion system is shown suitable as a method for determination of ex vivo tissue penetration 
(Machado et al., 2015; Sandri et al., 2004; Bonferoni et al., 2008; das Neves et al., 2013). Sheep vaginal 
epithelium is stratified squamous tissue, similar to that of human, only thinner (Moss et al., 2012). The 
tissue used in this experiment was from pregnant animals and the thickness was measured to be 750 µm. 
The experiment was performed in the presence of vaginal fluid simulant to closer mimic the conditions 
the delivery system is expected to face when administered vaginally. 
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In contrary to the strongly sustained release through the artificial membrane, penetration through the 
sheep vaginal tissue was prominent, and a distinct increase in IFN α-2b release from the PEGylated 
liposomes was seen (Figure 4). This demonstrates that the PEGylated liposomal formulation enables IFN 
α-2b to penetrate the vaginal mucus to a higher extent compared to the solution formulation used as a 
control. 
 
Figure 4: Ex vivo IFN α-2b penetration. Results are expressed as percentage mean ± SD (n = 3). 
*IFN α-2b in Intron A buffer 
 
Figure 5: IFN α-2b distribution after 8 hours ex vivo penetration experiment. 
*IFN α-2b in Intron A buffer 
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Majority of IFN α-2b from control solution appeared to be retained in or on top of tissue and only a minor 
amount of drug was able to penetrate through the tissue after 8 hours (Figure 5). 
 
3.5. Stability 
The stability of liposomal IFN α-2b has been confirmed for at least 1 month (Eppstein and Stewart, 1981). 
The physical and chemical properties of the environment might affect the stability and performance of the 
drug delivery system (Owen and Katz, 2005). The composition, volume, pH and rheological properties of 
vaginal fluids are affected by age, the menstrual cycle or sexual arousal. Some studies suggest that on 
average 0.5 – 0.75 g of vaginal fluid is contemporary present in the vagina (Owen and Katz, 1999). Vaginal 
pH in healthy, pre-menopausal women will vary from 4.0 – 5.0, however, the presence of semen will 
increase the pH to levels closer to neutral range. The average volume of human ejaculate is found to be 
3.4 mL (Owen and Katz, 2005), and expected to affect the vaginal pH for hours (das Neves et al., 2011). 
Based on the cited literature, PEGylated liposomes were diluted 1:10 (v/v) with vaginal fluid simulant and 
1:1 (v/v) with semen fluid simulant to determine possible IFN α-2b leakage from the delivery system once 
exposed to the vaginal environment. An incubation time of 2 hours was selected as an appropriate 
challenge. A minor leakage of merely 5.1 % IFN α-2b was detected after 2 hours, indicating the stability of 
PEGylated liposomes in a simulated vaginal environment and in the presence of semen fluid simulant. 
 
4. Conclusions 
Our findings suggest lack of interactions between mucin and PEGylated liposomes, confirming the 
mucoresistant properties provided when PEG is used as a coating material. The ability of the liposomally-
associated IFN α-2b to penetrate through the vaginal tissue was distinctively increased for the PEGylated 
liposomes as compared to IFN α-2b in solution. This indicates that PEGylation represents an approach to 
obtain drug delivery in the close proximity to the vaginal epithelium. Furthermore, the PEGylated 
liposomes were shown to be stable in the vaginal environment simulated by the presence of vaginal fluid 
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